STATE-OF-THE-ART PAPER
Atherothrombosis and High-Risk Plaque
Part I: Evolving Concepts
Valentin Fuster, MD, PhD, FACC*,
Pedro R. Moreno, MD, FACC*,*,
Zahi A. Fayad, PhD, FACC*,
Roberto Corti, MD, FACC and
Juan J. Badimon, PhD, FACC*
* Zena and Michael A. Wiener Cardiovascular Institute and the Marie-Josee and Henry R. Kravis Cardiovascular Health Center, The Mount Sinai School of Medicine, New York, New York
Department of Cardiology, University Hospital Zurich, Zurich, Switzerland
Manuscript received July 14, 2004;
revised manuscript received January 4, 2005,
accepted March 4, 2005.
* Reprint requests and correspondence: Drs. Pedro R. Moreno and Valentin Fuster, Mount Sinai School of Medicine, Box 1030, New York, New York, 10029. (Email: pedro.moreno{at}msnyuhealth.org).
 |
Abstract
|
|---|
Atherothrombosis is a complex disease in which cholesterol deposition, inflammation, and thrombus formation play a major role. Rupture of high-risk, vulnerable plaques is responsible for coronary thrombosis, the main cause of unstable angina, acute myocardial infarction, and sudden cardiac death. In addition to rupture, plaque erosion may also lead to occlusive thrombosis and acute coronary events. Atherothrombosis can be evaluated according to histologic criteria, most commonly categorized by the American Heart Association (AHA) classification. However, this classification does not include the thin cap fibroatheroma, the most common form of high-risk, vulnerable plaque. Furthermore, the AHA classification does not include plaque erosion. As a result, new classifications have emerged and are reviewed in this article. The disease is asymptomatic during a long period and dramatically changes its course when complicated by thrombosis. This is summarized in five phases, from early lesions to plaque rupture, followed by plaque healing and fibrocalcification. For the early phases, the role of endothelial dysfunction, cholesterol transport, high-density lipoprotein, and proteoglycans are discussed. Furthermore, the innate and adaptive immune response to autoantigens, the Toll-like receptors, and the mechanisms of calcification are carefully analyzed. For the advanced phases, the role of eccentric remodeling, vasa vasorum neovascularization, and mechanisms of plaque rupture are systematically evaluated. In the final thrombosis section, focal and circulating tissue factor associated with apoptotic macrophages and circulatory monocytes is examined, closing the link between inflammation, plaque rupture, and blood thrombogenicity.
|
Abbreviations and Acronyms
| | ACS = acute coronary syndrome | | AHA = American Heart Association | | apo = apolipoprotein | | CAM = cell adhesive molecule | | CRP = C-reactive protein | | HDL = high-density lipoprotein | | IEL = internal elastic lamina | | LDL = low-density lipoprotein | | MMP = matrix metalloproteinase | | NCP = non-collagenous bone-associated protein | | OPN = osteopontin | | TCFA = thin-cap fibroatheroma | | TF = tissue factor | | TLR = toll-like receptor |
|
|
Nomenclature and evolving assessment of disease
|
|---|
In the 19th century, there were two major hypotheses to explain the pathogenesis of atherosclerosis: the incrustation hypothesis, proposed by von Rokitansky in 1852, and the lipid hypothesis, proposed by Virchow in 1856 (1,2). These hypotheses focused on fibrin deposition, lipid accumulation, and extracellular matrix formation. In addition, Virchow used for the first time the name endarteritis deformans, linking inflammation to the disease and forming the basis of the response-to-injury hypothesis of Ross more than a century later (3–5). Lipoprotein retention (6) and chronic inflammation are intimately related to the early phases of the disease. Furthermore, inflammation also plays a role in plaque rupture and thrombosis (7–11). Therefore, the integration of these hypotheses can be unified under the term atherothrombosis.
Atherothrombosis is a systemic arterial disease originally involving mostly the intima of large- and medium-sized systemic arteries including the carotid, aorta, coronary, and peripheral arteries. The main components of atherothrombotic plaques are (12–18): 1) connective tissue extracellular matrix, including collagen, proteoglycans, and fibronectin elastic fibers; 2) crystalline cholesterol, cholesteryl esters, and phospholipids; 3) cells such as monocyte-derived macrophages, T-lymphocytes, and smooth-muscle cells; and 4) thrombotic material with platelets and fibrin deposition. Varying proportions of these components occur in different plaques, thus giving rise to a heterogeneity or spectrum of lesions. These components mainly affect the intima, but secondary changes also occur in the media and adventitia, (19) including growth of vasa vasorum (20–23). Atherosclerosis progresses through lipid core expansion and macrophage accumulation at the edges of the plaque, leading to fibrous cap rupture, as shown in Figure 1.
View larger version (168K):
[in this window]
[in a new window]
|
Figure 1 Cross-sectioned coronary artery containing a ruptured plaque with a non-occlusive platelet-rich thrombus superimposed. The actual defect in the fibrous cap is not seen in this section but is located nearby, documented by the presence of extravasated radiographic contrast medium (postmortem coronary angiography) in the soft, lipid-rich core just beneath the thin, inflamed fibrous cap. Trichrome stain, rendering thrombus red, collagen blue, and lipid colorless. Adapted with permission from Falk E and Fuster V. Atherogenesis and its determinants. In: Hursts the Heart. 10th edition. Fuster V, et al., editors. McGraw-Hill, 2001:1065–94.
|
|
To establish clinical risk factors for plaque rupture, Burke et al. (24) examined 113 men with coronary artery disease complicated with sudden cardiac death. Plaque rupture was associated with increased total cholesterol/high-density lipoprotein (HDL) ratio, but not with smoking or hypertension. Of note, ruptured plaques showed fibrous cap thickness (mean ± SD) of 23 ± 19 µm; 95% of ruptured caps measured 64 µm or less. As a result, vulnerable plaque was defined as a plaque with a fibrous cap <65 µm thick with an infiltrate of macrophages (>25 per high-magnification [0.3-mm diameter] field) (24), as shown in Figure 2.
View larger version (152K):
[in this window]
[in a new window]
|
Figure 2 Histologic example of a high-risk, vulnerable plaque. (a) Large lipid-rich core with a thin fibrous cap. The lumen contains contrast medium injected postmortem. (b) Higher magnification showing macrophages (>25 per high-power field) beneath a very thin cap (<65 µm in thickness). Extravasated erythrocytes with plaque hemorrhage within the core indicate plaque rupture nearby. Trichrome stain, rendering lipid colorless, collagen blue, and erythrocytes red. Adapted with permission from Schaar JA, et al. Eur Heart J 2004;25:1077–82.
|
|
Plaque rupture is the most common substrate for coronary thrombosis in humans. However, 30% to 40% of coronary thrombosis occurs at sites at which plaque rupture cannot be identified. In a landmark publication, Farb et al. (25) described 50 consecutive cases of sudden cardiac death attributable to coronary thrombosis, in which 22 had superficial erosion of a proteoglycan-smooth muscle cell–rich plaque. No site of cap rupture could be identified. To establish clinical and histologic characteristics, the remaining 28 cases of plaque rupture served as controls. Eroded plaques were more frequently seen in pre-menopausal women. Of note, eroded plaques were less stenotic, had lower macrophage infiltration, and had a much lower incidence of calcification, as shown in Figure 3.
View larger version (124K):
[in this window]
[in a new window]
|
Figure 3 Plaque erosion. Cross section of a coronary artery containing a stenotic atherosclerotic plaque with an occlusive thrombosis superimposed. The endothelium is missing at the plaque-thrombus interface, but the plaque surface is otherwise intact. Trichrome stain, rendering thrombus red, collagen blue, and lipid colorless. Courtesy of Dr. Erling Falk, Aarhus, Denmark.
|
|
Therefore, two different mechanisms, plaque rupture and erosion, can give rise to arterial thrombosis. The terms "high-risk" or "vulnerable" can be used as synonyms to describe plaques with an increased risk of thrombosis (26). In addition to these terms, other terms, including culprit lesion, inflamed thin-cap fibroatheroma (TCFA), calcific nodule, thrombosed plaque, and vulnerable patient, have been used. This multiple terminology has created confusion and, therefore, has required standardization. To properly define adequate terminology and avoid confusion, a written consensus from a group of experts properly standardized these terms, providing definitions for proper implementation (26), as summarized in Table 1.
|
Phases of atherothrombosis
|
|---|
According to a simplified modification of the criteria previously set forth by the American Heart Association (AHA) Committee on Vascular Lesions (14), and more recently by Stary (27), plaque progression can be subdivided into five pathologically/clinically relevant phases, as shown in Figure 4.
View larger version (40K):
[in this window]
[in a new window]
|
Figure 4 Clinicopathologic correlation of asymptomatic atherosclerosis leading to symptomatic atherothrombosis. Modified from Corti R, Fuster V. J Thromb Thrombolysis 2004;17:35–44.
|
|
Phase 1 (early).
Lesions are small, commonly seen in young people, and categorized into three types as follows: type I lesions, consisting of macrophage-derived foam cells that contain lipid droplets; type II lesions, consisting of both macrophages and smooth-muscle cells and mild extracellular lipid deposits; and type III lesions, consisting of smooth-muscle cells surrounded by extracellular connective tissue, fibrils, and lipid deposits.
Phase 2 (advanced).
Lesions, although not necessarily stenotic, may be prone to rupture because of their high lipid content, increased inflammation, and thin fibrous cap. These plaques are categorized morphologically as one of two variants: type IV lesions, consisting of confluent cellular lesions with a great deal of extracellular lipid intermixed with normal intima, which may predominate as an outer layer or cap; or type Va lesions, possessing an extracellular lipid core covered by an acquired fibrous cap. Phase 2 plaques can evolve into the acute phases 3 and 4.
Phase 3.
These lesions are characterized by acute complicated type VI lesions, originating from ruptured (type IV or Va) or eroded lesions, and leading to mural, non-obstructive thrombosis. This process is clinically silent, but occasionally may lead to the onset of angina (10).
Phase 4.
These lesions are characterized by acute complicated type VI lesions, with fixed or repetitive occlusive thrombosis. This process becomes clinically apparent in the form of an acute coronary syndrome (ACS), although not infrequently it is silent (28,29). About two-thirds of ACS are caused by occlusive thrombosis on a non-stenotic plaque, although in about one-third, the thrombus occurs on the surface of a stenotic plaque (7). In phases 3 and 4, changes in the geometry of ruptured plaques, as well as organization of the occlusive or mural thrombus by connective tissue, can lead to the occlusive or significantly stenotic and fibrotic plaques.
Phase 5.
These lesions are characterized by type Vb (calcific) or Vc (fibrotic) lesions that may cause angina; however, if preceded by stenosis or occlusion with associated ischemia, the myocardium may be protected by collateral circulation and such lesions may then be silent or clinically inapparent (30,31).
The AHA classification falls short of identifying plaque erosion or the TCFA. A different classification including these two categories has been proposed by Virmani et al. (32), as shown in Figure 5.
View larger version (31K):
[in this window]
[in a new window]
|
Figure 5 Simplified scheme representing seven categories of lesions. Dashed lines reflect controversy regarding etiology. The processes leading to lesion progression are listed between categories. Reproduced with permission from Virmani R, et al. Arterioscler Thromb Vasc Biol 2000;20:1262.
|
|
|
Early atherothrombosis
|
|---|
Endothelial dysfunction.
The endothelium is a dynamic autocrine and paracrine organ that regulates anti-inflammatory, mitogenic, and contractile activities of the vessel wall, as well as the hemostatic process within the vessel lumen (33) (Fig. 6). A single molecule, nitric oxide (NO), is responsible for these regulatory processes (34).
View larger version (115K):
[in this window]
[in a new window]
|
Figure 6 Healthy endothelium under laminar flow conditions and no risk factors. A single molecule, nitric oxide (NO), is involved in multifactorial pathways preventing monocyte adhesion, platelet aggregation, and smooth muscle cell proliferation. PGI2 = prostacyclin 2; SMC = smooth muscle cell; tPA = tissue plasminogen activator.
|
|
A dysfunctional endothelium, characterized by decreased NO synthesis, facilitates vessel wall entry and oxidation of circulating lipoproteins, monocyte entry and internalization or inflammation, smooth cell proliferation and extracellular matrix deposition, vasoconstriction, as well as a pro-thrombotic state within the vessel lumen (35,36) (Fig. 7).
View larger version (123K):
[in this window]
[in a new window]
|
Figure 7 Diseased endothelium with non-laminar flow, low-density lipoprotein (LDL) deposition, cell adhesion molecule (CAM) expression, macrophage migration, tissue factor (TF), and matrix metalloproteinase (MMP) expression leading to smooth muscle cell (SMC) proliferation and vasa vasorum neovascularization. PDGF = platelet-derived growth factor; PAI-1 = plasminogen activator inhibitor-1; TXA2 = thromboxane A2.
|
|
Endothelial dysfunction, traditionally known as the earliest manifestation of atherothrombosis, is often the result of a disturbance in the physiological pattern of blood flow—flow reversal or oscillating shear stress—at bending points and near bifurcations. (37,38). In addition to biomechanical shear forces enhanced by hypertension (39), the coexistence of other biohumoral risk factors such as hypercholesterolemia, advanced glycation end-products in diabetes and in elderly people, chemical irritants in tobacco smoke, circulating vasoactive amines, and immunocomplexes, have been associated with endothelial dysfunction (40–42) (Fig. 7).
Endothelial cells respond to changes in local shear rates by modulating the induction and/or repression of several genes. A common mechanism of action of the gene modulation in part seems to be mediated via shear stress responding elements located in the genes (43). Thus, as a response to reversal or oscillatory shear stress, endothelial cell activation is characterized by the expression of cell adhesive molecules (CAMs) (Fig. 7) from the selectin superfamily (E- and P-selectins). These proteins facilitate the homing (margination and adhesion) of the circulating monocytes to the activated endothelial cells. The expression of the selectins is regulated by the transcriptional nuclear factor (NF)-kappa-B (44) and is followed by the expression of other CAMs (i.e., intercellular and vascular adhesive molecules-1). These proteins will facilitate the internalization of the adhered monocytes into the arterial wall, contributing to atherogenesis. Furthermore, clinical studies have associated high plasma levels of these proteins with an increased risk for coronary events (45–48).
Lipoprotein transport and proteoglycans.
Low-density lipoproteins (LDLs) infiltrate through the arterial endothelium into the intima (49) (Fig. 7). This binding seems to relate to an ionic interaction of apolipoprotein (apo) B with matrix proteins including proteoglycans, collagen, and fibronectin (50). Proteoglycans are macromolecules composed of a core protein and long-chain carbohydrates called glycosaminoglycans. Proteoglycans along with other extracellular matrix proteins are located between the basement membrane of the endothelial cell and the internal elastic lamina (IEL). The interactions between oxidized LDL and proteoglycans are crucial in early atherosclerosis, mostly related to lipoprotein retention (6), intravascular aggregation of LDL leading to chemical modification, and induction of inflammation (50).
Another important feature of lipoprotein transport is related to the effect of HDL. Classically known as the antiatherogenic lipoprotein, HDL promotes reverse cholesterol transport from the arterial wall, specifically from lipid-laden macrophages (51–55). The first experimental evidence supporting this theory was reported by our group in the hypercholesterolemic rabbit model. Once-per-week administration of HDL inhibited progression and induced regression of macrophage-rich aortic lesions (56,57). Further inhibition of atherosclerosis was then obtained in apoE-null mice using the Apo A-I (Apo A-IMilano) complex (58–60). These beneficial effects were recently reproduced in human coronary lesions using once-per-week administration of synthetic HDL made from Apo A-IMilano in patients with symptomatic coronary artery disease (61). The HDL sub-fractions may play a role in these beneficial effects, with HDL2 being the most important for reverse lipid transport. Despite its protective effects, patients with high HDL plasma levels still can present with ACS, probably related to elevations in HDL3 rather than in HDL2 (62). Furthermore, the concomitant use of antioxidant supplements blocks the beneficial effects of niacin and statins and may play a role in recurrent symptoms in patients with high HDL levels and coronary artery disease (63).
Innate and adaptive immune response to auto-antigens.
The important role of inflammation in atherothrombosis has focused attention on the immune system. Development of atherosclerosis is influenced by innate and adaptive immune responses (64,65). Innate immunity represents the first inflammatory response to microorganisms and pathogens. It is based on detection by pattern recognition on macrophages and dendritic cells (66). Several pattern recognition receptors bind a wide range of proteins, carbohydrates, lipids, and nucleic acids. The most important receptors for innate immunity in atherothrombosis are the scavenger receptors and the toll-like receptors (TLRs) (67).
In the first line of innate immunity, the scavenger receptors SR-A and CD-36 are responsible for the uptake of oxidized LDL, transforming the macrophage into a foam cell. (68,69). Furthermore, this pathway activates the NF-kappa-B nuclear transcriptional factor, triggering a potent chemoattractant cycle of monocyte migration and macrophage/foam cell formation (i.e., monocyte chemoattractant protein [MCP]-1, leukotriene LTB4, and monocyte-colony stimulating factor [M-CSF]) (68–70). Macrophage/foam cells produce cytokines that activate neighboring smooth-muscle cells, resulting in extracellular formation and fibrosis (18).
The second line of innate immunity, the TLRs, has gained significant recognition recently. For example, the receptor for bacterial lipopolysaccharides, TLR4, is known to recognize cellular fibronectin and heat shock proteins, endogenous peptides produced during tissue injury that may act as auto-antigens early in the disease (71–73). The TLR4 co-localizes with fibroblasts and macrophages in the adventitia and the intima of human coronary atherothrombosis. Stimulation of TLR4-induced activation of NF-kappa-B and increased mRNAs of various cytokines (74). Furthermore, adventitial TLR4 activation augmented neointima formation in a mouse model, suggesting a link between the immune receptor TLR4 and intimal lesion formation (74). More recently, TLR4 has been shown to be involved not only in the initiation but also in progression and expansive remodeling of atherothrombosis (75,76).
Adaptive immunity is much more specific than innate immunity but may take several days or even weeks to be fully mobilized. It involves an organized immune response leading to generation of T and B cell receptors and immunoglobulins, which can recognize foreign antigens. This type of immunity may provide the basis for great advances in the near future, such as immunization and immunosuppressive drugs, which usually target adaptive immune responses. There is certainly a long way to go, but current efforts are setting the foundation to one day produce a vaccine against atherothrombosis (77).
Mechanisms of calcification.
In addition to immunity, the mechanisms of atherosclerotic calcification have gained significant relevance within the last few years. Coronary calcification is composed of both hydroxyapatite and organic matrix, including type I collagen and non-collagenous bone-associated proteins (NCPs) (78). Collagen-associated crystal deposition initiates mineralization within matrix vesicles, leading to the concept that dystrophic calcification is an active, regulated process rather than passive accumulation of mineral. In addition to collagen, NCPs also play a major role. The most relevant NCPs associated with vascular calcification include osteopontin (OPN), osteonectin, osteoprotegerin, and matrix Gla protein, as shown in Table 2.
The most studied NCP in atherothrombosis is osteopontin, which was identified by immunohistochemistry in atherosclerotic plaques (79) and is highly expressed by macrophages in the intima of human arteries (80). The role of OPN mRNA is up-regulated in calcific aortas of LDL receptor-deficient mice fed either high-fat diabetogenic diet (81). Osteopontin expression was detected in peri-aortic adventitial cells, aortic vascular smooth muscle cells, and macrophages of the intimal atheroma. This suggests that OPN-mediated vascular calcification can occur independently of atheroma formation, and that vascular calcification can originate from an osteoprogenitor cell population in the adventitia. Hence, the identification of vascular calcification does not necessarily imply growing atheroma. On the other hand, the functional role of OPN after vascular injury was tested in the rat carotid model two weeks after catheter denudation. The use of anti-OPN antibody decreased intimal areas and cell numbers by 33% and 31%, respectively (82). The OPN promotes vascular cell adhesion and is chemotactic for smooth muscle cells (83). Furthermore, OPN expression is up-regulated by glucose levels, suggesting an active role for OPN in diabetic vasculopathy (84,85).
As it relates to calcification of human atheroma, early microcalcifications can be observed in transitional lesions (AHA classification III and IV), as shown in Figure 8A. As lesions fibrose, calcification becomes dense, as seen in advanced atherosclerosis, seen in Figure 8B.
View larger version (143K):
[in this window]
[in a new window]
|
Figure 8 Examples of human atherosclerotic calcification. (A) Microcalcifications identified by light microscopy within the lipid core of a transitional (type IV) coronary plaque (black arrows). (B) Coarse calcification seen in an advanced (type Vb) coronary plaque. Reproduced with permission from Stary HC. A Slide Atlas of Atherosclerosis Progression and Regression. New York, NY: Parthenon Publisher Group Inc., 1999.
|
|
|
Advanced atherothrombosis
|
|---|
Continuous exposure to the systemic, pro-atherogenic milieu will increase chemotaxis of monocytes leading to lipid accumulation, necrotic core, and fibrous cap formation, evolving into advanced atherosclerosis. Well-established patterns of inflammation and metalloproteinase expression extensively described within the last decade leads to plaque rupture, often found at the shoulder of large lipid-rich plaques (9–11). More recently, new structural and functional features characterizing these lesions have been identified, including eccentric plaque growth with compensatory enlargement of the vessel wall, also known as vascular remodeling, and vasa vasorum neovascularization leading to lipid core expansion and intra-plaque hemorrhage, and lipid core expansion.
Eccentric vascular remodeling.
Eccentric growth of atheroma involving the inner components of the vessel wall before obstructing the lumen is also known as vascular remodeling. Described by Glagov et al. in 1987 (86), remodeling has been consistently identified in atherosclerotic lesions responsible for unstable coronary syndromes. Furthermore, atherosclerotic plaques undergoing remodeling are characterized by a larger lipid core, fewer smooth muscle cells, and increased macrophage infiltration (87). As the plaque grows eccentrically within the vessel wall rather than concentrically into the lumen, remodeling triggers crucial changes within the tunica media and the adventitia. Several studies have shown increased macrophage-derived matrix metalloproteinase-2 and -9 expression within the intimomedial interface of remodeled plaques (88). The increased activity of metalloproteinases digests the IEL, modulating the process of remodeling. More recently, our group identified disruption of the IEL as an independent predictor of plaque rupture (19). A strong association between the histologic evidence of IEL disruption and fibrous cap rupture was identified in 598 human aortic plaques. In addition, increased inflammation, fibrosis, and atrophy within the tunica media were documented. Furthermore, adventitial inflammation was increased in ruptured plaques when compared with non-ruptured plaques (19). Concordantly, Burke et al. (89) showed that marked expansion of the IEL occurred in plaque hemorrhage with or without rupture. On the contrary, shrinkage of the IEL was found in plaque erosion and total occlusions. Using multivariate analysis, the plaque components most strongly associated with eccentric remodeling were macrophage infiltration, calcification, and lipid core area, linking the concept of remodeling with plaque vulnerability. Therefore, structures such as the IEL, tunica media, and adventitia, involved in the process of eccentric remodeling and historically considered inactive structures in the pathogenesis of atherothrombosis, seem to be actively involved in the development and complications of atherosclerotic disease and may even play a role in precipitating acute coronary syndromes.
Vasa vasorum neovascularization.
Nourishment of normal blood vessels is accomplished by oxygen diffusion from the lumen of the vessel or from adventitial vasa vasorum. When vessel wall thickness exceeds the effective diffusion distance of oxygen, vasa vasorum proliferates in the inner layers of the vessel wall, where it is normally absent. Macrophages, attracted by oxidized LDL, are responsible for cytokine production driving neovessel growth (90,91). Therefore, intimal disease is considered a prerequisite for vessel wall and plaque neovascularization. Recent observations have identified increased neovessel density in the outer layers of the artery as the vessel wall undergoes eccentric remodeling. In the Glagov et al. (86) seminal work, the first step of remodeling was characterized by overexpansion of the vessel wall in preparation for plaque growth. This crucial observation received almost no attention until recently, when experimental studies documented extensive coronary vasa vasorum neovascularization simultaneously with overexpansion of the vessel wall within the first two to four weeks of a hypercholesterolemic diet in the swine model (92). Of note, increased neovascularization was present in animals with normal endothelial-dependent vasodilation, which became impaired only after 6 to 12 weeks of a high-cholesterol diet (92). Therefore, vasa vasorum neovascularization may play a crucial role in the pathogenesis of atherosclerosis (93–101).
Vasa vasorum surrounds and penetrates the adventitia and outer media of large vessels, including the aorta and the coronary, femoral, and carotid arteries (102). Vasa vasorum can originate from several different sites. In the coronary arteries, vasa vasorum originates from bifurcation segments of epicardial vessels; in the ascending aorta, vasa vasorum originates from coronary and brachiocephalic arteries; in the descending thoracic aorta, vasa vasorum originates from intercostal arteries; and in the abdominal aorta, vasa vasorum arises from the lumbar and mesenteric arteries (95). There are two anatomically distinct patterns of vasa vasorum; first-order vasa vasorum run longitudinally to the lumen of the host vessel, whereas second-order vasa vasorum are arranged circumferentially around the host vessel (Fig. 9). Their main function is to nurture the vessel wall with a number that remains constant throughout life (103). However, atherosclerotic vasa vasorum can proliferate, leading to extensive neovascularization involving the tunica media and directed towards lipid-rich atheroma (104,105).
View larger version (107K):
[in this window]
[in a new window]
|
Figure 9 Coronary neovessels from adventitial vasa vasorum nurture the vessel wall through the first order (parallel) and the second order (perpendicular). Reproduced with permission from Kwon HM, et al. J Clin Invest 1998;101:1551–6.
|
|
Our group evaluated the role of vasa vasorum in complex atherothrombosis comparing neovessel content in ruptured and non-ruptured plaques. Double immunohistochemistry was used to identify neovessels, macrophages, and T cells (Fig. 10). Neovessel content was significantly increased in ruptured plaques when compared with non-ruptured plaques in the human aorta (20). We identified neovascularization with monocyte-rich inflammation and disruption of the IEL (presumably as a result of monocyte-released MMPs), as significant contributors to plaque rupture.
View larger version (134K):
[in this window]
[in a new window]
|
Figure 10 (A) High-power image of microvessels identified with the monoclonal endothelial cell marker CD34 linked to a blue chromogen. (B) High-power image from the plaque shoulder region showing CD34-positive microvessels in blue contrasting sharply with CD68/CD3-positive inflammatory cells linked to a red chromogen. (C) Microvessels at the tunica media (purple chromogen) contrasting with smooth muscle cells linked to a brown chromogen using alpha-actin marker. (D) Corresponding high power from C, showing disarray of smooth muscle cells in brown and microvessels in purple. Reproduced with permission from Moreno PR, et al. Circulation 2004;110:2032–8.
|
|
More recently we have identified increased microvessel content in atherothrombotic lesions from patients with diabetes mellitus (106). Furthermore, ruptured plaques from patients with diabetes mellitus have increased neovascularization when compared with ruptured plaques from patients without diabetes (107). Of note, microvessels are associated with macrophages and T cell lymphocytes (108). When analyzing diabetes neovascularization, microvessel morphology is characterized by a complex morphology including sprouting, red blood cell and monocyte extravasation with macrophage erythrophagocytosis (109). Furthermore, histologic evidence for atherothrombotic neovascularization as a pathway for macrophage infiltration was documented (110), as shown in Figure 11.
View larger version (179K):
[in this window]
[in a new window]
|
Figure 11 Microvessels as a pathway for macrophage entry/exit to atherosclerotic plaques. High-power image showing CD34-positive microvessels (blue) and intraluminal, monocyte-derived macrophages (red) circulating within the plaque, as highlighted by the red arrows. Courtesy of Dr. Purushothaman, Mount Sinai Hospital, 2005.
|
|
Vasa vasorum may also be involved in the process of plaque regression. When compared with lipid-rich plaques, fibrocalcific lesions with reduced lipid area, also known as regression type lesions, had the lowest microvessel content (111). Most importantly, fibrocalcific, regression-type lesions from diabetic patients are no longer vascularized, suggesting that microvessel involution may be a marker for plaque stabilization (112). Of clinical relevance, Corti et al. (113) recently documented for the first time the morphologic pathway for plaque regression occurring from the adventitia. Therefore, vasa vasorum may serve as a potential pathway for reverse lipid transport. As cholesterol exits the plaque, neovascularization and the outer layers of the vessel wall experience regression, as documented experimentally in non-human atherosclerotic primates with documented plaque regression (96).
|
Plaque rupture
|
|---|
Two mechanisms independently or in conjunction trigger plaque rupture. The first one is related to physical forces and occurs most frequently where the fibrous cap is thinnest, most heavily infiltrated by foam cells, and therefore weakest (Figs. 2 and 12). 
View larger version (71K):
[in this window]
[in a new window]
|
Figure 12 Plaque vulnerability, disruption, and thrombosis: anatomical changes leading to acute coronary syndrome and subsequent plaque remodeling. An element of vasoconstriction is usually present. Modified with permission from Theroux and Fuster (136).
|
|
For eccentric plaques, this is often the shoulder or between the plaque and the adjacent vessel wall (114). Specifically, pathoanatomic examination and in vitro mechanical testing of isolated fibrous caps indicated that vulnerability to rupture depends on several factors (7,32,114), circumferential wall stress or cap fatigue; location, size, and consistency of the atheromatous core; and blood flow characteristics, particularly the impact of flow on the proximal aspect of the plaque (i.e., configuration and angulation of the plaque).
The second mechanism involves an active process within the plaque leading to rupture. Atherectomy specimens from patients with ACS reveal areas very rich in macrophages (11) and mast cells (115). These cells are capable of degrading extracellular matrix by phagocytosis or secretion of proteolytic enzymes; thus, enzymes such as plasminogen activators and matrix metalloproteinases (MMPs), including collagenases, elastases, gelatinases, and stromelysins, by degrading the components of extracellular matrix, may weaken the fibrous cap and predispose it to rupture (116,117). In in vitro conditions, human monocyte-derived macrophages have been observed to degrade collagen of the fibrous cap while simultaneously expressing MMP-1 (interstitial collagenase) and inducing MMP-2 (gelatinolytic) activity in the culture medium—actions that can be prevented by MMP inhibitors (7,116). Certain MMPs observed in human coronary plaques and foam cells may be particularly active in destabilizing plaques (118,119). Furthermore, quantification of certain MMPs and their inhibitors in blood has been correlated with the degree of atherogenesis in humans (120).
The MMPs are also involved in several non-atherosclerotic processes within the heart (121–126). Most importantly, as previously mentioned, disruption of the IEL as a result of the adventitia/media infiltrated by monocytes, which release MMPs mostly at areas of neovascularization. This appears to contribute significantly to plaque rupture (19,88).
The continuing entry, survival, and replication of monocytes/macrophages within plaques are partly dependent on factors such as CAMs, MCP-1, and M-CSF (48,68,127–129). Cytokines regulate macrophage uptake of modified lipoprotein by way of scavenger receptors. Most importantly, interferon-gamma, tumor necrosis factor-alpha, and interleukin-1 activate macrophage apoptosis (68,130). Thus, macrophages, following what appears to be a defensive mission to protect the vessel wall from lipoprotein accumulation, may eventually undergo apoptotic death (68,70,131). This phenomenon leads to the shedding of membrane microparticles, causing exposure of phosphatidylserine on the cell surface, a major contributor for arterial thrombosis after plaque rupture (70,131). Recent work by our group seems to indicate apoptosis as the common link between inflammation and thrombosis. Thus, Hutter et al. (132,133) have shown an excellent correlation between macrophage density, apoptosis markers, and tissue factor (TF) expression in human and mouse atherosclerotic lesions.
Other inflammatory cells found in intact and disrupted plaques include mast cells present in the shoulder regions but in fairly low densities (115). They can secrete powerful proteolytic enzymes such as tryptase and chymase that subsequently activate the proenzymatic form of MMPs. Finally, the role of neutrophils is less clear (18,117,134). They are rare in intact plaques, and it is likely that they enter shortly after rupture.
|
Thrombotic complications
|
|---|
Acute coronary thrombosis.
Rupture of a high-risk vulnerable plaque changes plaque geometry and triggers coronary thrombosis (7). Such a rapid change in plaque geometry may result in acute occlusion or subocclusion with clinical manifestations of unstable angina or other ACS (135,136). More frequently, however, the rapid changes seem to result in mural thrombus without evident clinical symptoms. Thrombus organization mediated by repaired collagen (type III) heals the rupture site, but increases plaque volume, contributing to the progression of atherothrombosis (135,136). More specifically, a number of factors—plaque-dependent thrombogenic substrate, rheology, and systemic procoagulant activity—may influence the magnitude and stability of the resulting thrombus and thus, the severity of the coronary syndrome (24,137), as shown in Table 3.
Plaque-dependent thrombogenic substrate
Exposure of a thrombogenic substrate is a key factor in determining thrombogenicity at the local arterial site (Table 3). Heterogeneity of plaque composition varies even within the same subject, as shown in Figure 13.
View larger version (134K):
[in this window]
[in a new window]
|
Figure 13 Atherothrombosis: a variable mix of chronic atherosclerosis and acute thrombosis. Cross-sectioned arterial bifurcation illustrating a collagen-rich (blue-stained) plaque in the circumflex branch (left) and a lipid-rich and ruptured plaque with a non-occlusive thrombosis superimposed in the obtuse branch (right). C = contrast in the lumen; Ca = calcification; T = thrombosis. Adapted from Falk E, Prediman S, Fuster V. Coronary plaque disruption. Circulation 1995;92:657–71.
|
|
Data on the thrombogenicity of ruptured atherosclerotic lesions are limited. Using an original perfusion chamber, we exposed different types of human aortic plaques to flowing blood and their thrombogenicity was assessed. Lipid-rich plaques were by far the most thrombogenic of all, which explains why rupture of lipid-rich plaques is the most frequent cause of coronary thrombosis in ACS. In addition, thrombogenicty was modulated by TF content, mostly located in macrophage-rich areas. (138–140). Residual mural thrombus in itself was also highly thrombogenic, presumably as a result of monocyte/TF-related activation (141,142) with generation of thrombin (143,144).
Tissue factor, a small-molecular-weight glycoprotein, initiates the extrinsic clotting cascade and is believed to be a major regulator of coagulation, hemostasis, and thrombosis (145). Tissue factor forms a high-affinity complex with coagulation factors VII/VIIa; TF/VIIa complex activates factors IX and X, which in turn leads to thrombin generation, as shown in Figure 14 (141,146).
View larger version (160K):
[in this window]
[in a new window]
|
Figure 14 Interactions between platelet activation, tissue factor (TF) vesicle expression from plaque macrophages, and activation of the coagulation cascade. Ca2+ = calcium; vWF = von Willebrand factor.
|
|
Co-localization analysis of coronary atherectomy specimens from patients with unstable angina showed a strong relation between TF and macrophages (147). This relation suggests a cell-mediated thrombogenicity in patients with unstable angina and ACS. Furthermore, TF is particularly present in apoptotic macrophages, highlighting the role of local TF in ACS (70,131,148). In addition, specific inhibition of vascular TF by the use of r-tissue factor pathway inhibitor was associated with a significant reduction of acute thrombus formation in human lipid-rich plaques (149) and in pig injured plaques (150). Conversely, native tissue factor pathway inhibitor degradation after thrombolysis may enhance procoagulant activity at these sites of TF expression, thus contributing to early reocclusion after thrombolysis in myocardial infarction (151,152). Such observations document the active role of TF in coronary thrombosis and open a new therapeutic strategy in the prevention of ACS (153).
Rheology and thrombosis
The degree of stenosis caused by the ruptured plaque and the overlying mural thrombi are also key factors for determining thrombogenicity at the local arterial site (Table 3). Specifically, shear rate is directly related to flow velocity and inversely related to the third power of the lumen diameter. Thus, acute platelet deposition after plaque rupture is highly modulated by the degree of narrowing after rupture. Changes in geometry may increase platelet deposition, whereas sudden growth of thrombus at the injury site may create further stenosis and thrombotic occlusion. Most platelets are deposited at the apex of a stenosis, where the highest shear rate develops (154,155). Furthermore, mural thrombus formation may contribute to vasoconstriction originated from platelets—serotonin and thromboxane A2 (156)—increasing shear force-dependent platelet deposition (135,157,158).
Systemic procoagulant activity
As previously discussed, 30% of coronary thrombosis occurs at sites of superficial erosion of a fibrotic plaque (Fig. 3) (24,25,32). Thus, complicated thrombi in such cases may well be dependent on a hyper-thrombotic state triggered by systemic factors (2). Two major pathways are deeply involved in systemic procoagulant activity: coronary risk factors and circulating tissue factor.
Changes in lipid metabolism, cigarette smoking, hyperglycemia, hemostasis, and others are associated with increased blood thrombogenicity (141,159–162) (Table 3). Elevated LDL cholesterol levels increase blood thrombogenicity and growth of thrombus under defined rheology conditions (163,164). Reducing LDL cholesterol levels using statins decreased thrombus growth by approximately 20% (164). Smoking increases catecholamine release, potentiating platelet activation (165) and increasing fibrinogen levels (166). Catecholamine-dependent effects may explain the increased incidence of sudden death and acute cardiovascular events after emotional and physical stress (141,167). Patients with diabetes, especially those with poorly controlled diabetes, have increased blood thrombogenicity (168–170). Platelets from patients with diabetes have increased reactivity and hyper-aggregability and expose a variety of activation-dependent adhesion proteins (169–171); such abnormal platelet function is reflected by increased platelet consumption and increased accumulation of platelets on the altered vessel wall (171–173). Recent observations indicate that the thrombogenic state associated with high LDL cholesterol, cigarette smoking, and diabetes may share a common biological pathway. That is, an activation of leukocyte-platelet interactions associated with release of TF and thrombin activation has been observed in these conditions (141,170), being more particularly studied in the diabetic population (120–124), Furthermore, reversal of such risk factors may alter such cell-cell interactions, being particularly studied with the statins (174–176).
Recent studies showed increased levels of circulating TF antigen in patients with cardiovascular disease (177) and coagulation disorders, such as disseminated intravascular coagulation (178,179). Circulating TF antigen has been associated with increased blood thrombogenicity in patients with ACS (177,180) and chronic coronary artery disease (181). Furthermore, Increased TF-positive procoagulant microparticles are present in the circulating blood of patients under pathophysiologic conditions (182). Thus far, the cellular origin of TF-positive microparticles in the circulating blood has not been established. As described, atherosclerotic plaques have been shown to contain TF that is associated with macrophages within the lesion (147). High levels of shed apoptotic microparticles are found in extracts from atherosclerotic plaques (70,131). These microparticles with increased TF activity seem to be of monocytic origin, suggesting a causal relationship between shed membrane microparticles and procoagulant activity of plaque extracts. In addition, TF has also been identified within thrombi formed in coronaries (140,147). Immunoelectron microscopy showed TF in thrombi within 5 min of formation, mainly localized on membrane vesicles attached to platelets and fibrin strands (183,184). Neutrophils and monocytes have been isolated from the circulating blood using anti-TF antibodies (183). Thus, aside from apoptotic macrophages and microparticles from atherosclerotic plaques, activated monocytes in the circulating blood seem to be a source of TF microparticles and may represent the result of the activation by the aforementioned risk factors and others, so contributing to thrombotic events (140,141), as shown in Figure 14. Indeed, the predictive value of C-reactive protein (CRP) and CD40L may in part be a manifestation of such systemic phenomena; CRP, like fibrinogen, is a protein of the acute-phase response and a sensitive marker of low-grade inflammation. It is produced in the liver as a result of mediators such as interleukin-6 generated by inflammation in the vessel wall (i.e., macrophages) or extravascularly (i.e., circulating monocytes) (185). Increased levels of CRP have been reported to independently predict acute coronary events (186) even in people whose blood lipid values are below the median levels in the population (187,188). Furthermore, statin therapy prevented coronary events in individuals with high CRP and relatively normal LDL cholesterol values (187). Of interest, the lowering effect of statin on CRP values was independent of its effect on lipid levels. Whether CRP reflects the inflammatory component of atherosclerotic plaques or of the circulating blood and whether it is a surrogate marker or a biologically active element in the process of plaque development or thrombus formation is not known (185,189). However, recent studies support that CRP is an activator of blood monocyte and vessel wall endothelial cells (189–192). This encourages further investigation into the effect of certain risk factors in the activation of inflammation of the vessel wall and circulating blood, probably leading to an active role of TF, CRP, and perhaps CD40 (193,194) as local and systemic key factors in the process of atherothrombosis.
Acute thrombosis and emboli of non-coronary arteries (Table 4).
Thrombosis and thromboemboli originated in carotid plaques are frequently the result of rupture or dissection of a heterogenous plaque, presumably as a result of the impact of the systemic high-energy blood flow against the resistance offered by the plaque (195,196). Intra-plaque hemorrhage caused by the rupture of vasa vasorum may play a significant role. Plaque rupture with exposure of lipid-rich material has also been documented as a common form of stroke (197–202). Thrombosis and thromboemboli from the thoracic aorta is also a consequence of plaque rupture (114,143,144), probably related to mechanisms similar to those described in about two-thirds of acute coronary thrombosis (114). Thrombosis of the peripheral arteries is most frequently observed in the surface of stenotic and fibrotic plaques, as described in about one-third of acute coronary thrombosis (203,204). Peripheral atherothrombosis is predominantly the consequence of a thrombogenic systemic blood associated with certain risk factors described previously (i.e., smoking, diabetes, hyperlipidemia) (203,205–207). Finally, acute occlusion of the peripheral vasculature frequently results from thromboemboli of cardiac or abdominal aortic origin (203,206,207).
|
Conclusions
|
|---|
Atherothrombosis is a complex disease in which cholesterol deposition, inflammation, and thrombus formation play a major role. High-risk, vulnerable plaque is responsible for acute coronary thrombosis, leading to clinical manifestations of unstable angina, acute myocardial infarction, and sudden cardiac death. Plaque rupture is the most common trigger of thrombosis. However, plaque erosion also plays a significant role. Atherothrombosis can be classified according to histologic criteria, most commonly known as the AHA classification. However, this classification does not include plaque erosion or the thin-cap fibroatheroma. As a result, new classifications have emerged. The disease is asymptomatic during a long period, and dramatically changes its course when complicated by thrombosis. This is summarized in five phases, from early lesions to plaque rupture, thrombosis and plaque healing, followed by fibrocalcification. Recent studies have documented increased neovascularization and intra-plaque hemorrhage in complex atherothrombosis. Tissue factor, the most potent trigger of the coagulation cascade, seems to be critical for plaque thrombogenicity. Circulating tissue factor microparticles seem also associated with circulating monocytes, closing the link between inflammation, plaque rupture, and thrombogenicity.
|
Acknowledgments
|
|---|
The authors thank Drs. K. Raman Purushothaman, Erling Falk, Jose Meller, and Angelica Steinheimer for providing high-quality images, supportive information, and editorial support.
|
References
|
|---|
1. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (1) N Engl J Med 1992;326:242-250.[Web of Science][Medline]
2. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (2) N Engl J Med 1992;326:310-318.[Web of Science][Medline]
3. Ross R, Glomset JA. The pathogenesis of atherosclerosis (first of two parts) N Engl J Med 1976;295:369-377.[Web of Science][Medline]
4. Ross R, Glomset JA. The pathogenesis of atherosclerosis (second of two parts) N Engl J Med 1976;295:420-425.[Web of Science][Medline]
5. Ross R. Atherosclerosis—an inflammatory disease N Engl J Med 1999;340:115-126.[CrossRef][Web of Science][Medline]
6. Williams KJ, Tabas I. The response-to-retention hypothesis of early atherogenesis Arterioscler Thromb Vasc Biol 1995;15:551-561.[Free Full Text]
7. Falk E, Shah PK, Fuster V. Coronary plaque disruption Circulation 1995;92:657-671.[Free Full Text]
8. Libby P. Molecular bases of the acute coronary syndromes Circulation 1995;91:2844-2850.[Free Full Text]
9. Libby P. Atherosclerosisthe new view. Sci Am 2002;286:46-55.[Web of Science][Medline]
10. Davies MJ. Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995 Circulation 1996;94:2013-2020.[Free Full Text]
11. Moreno PR, Falk E, Palacios IF, Newell JB, Fuster V, Fallon JT. Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture Circulation 1994;90:775-778.[Abstract/Free Full Text]
12. Stary HC. Composition and classification of human atherosclerotic lesions Virchows Arch 1992;421:277-290.
13. Stary HC, Chandler AB, Glagov S, et al. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association Circulation 1994;89:2462-2478.[Abstract/Free Full Text]
14. Stary HC, Chandler AB, Dinsmore RE, et al. A definition of advanced types of atherosclerotic lesions and a histologic classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association Circulation 1995;92:1355-1374.[Abstract/Free Full Text]
15. Schwartz SM, deBlois D, O’Brien ER. The intima. Soil for atherosclerosis and restenosis Circ Res 1995;77:445-465.[Free Full Text]
16. Daugherty A, Pure E, Delfel-Butteiger D, et al. The effects of total lymphocyte deficiency on the extent of atherosclerosis in apolipoprotein E–/– mice J Clin Invest 1997;100:1575-1580.[Web of Science][Medline]
17. Daugherty A, Rateri DL. T lymphocytes in atherosclerosisthe yin-yang of Th1 and Th2 influence on lesion formation. Circ Res 2002;90:1039-1040.[Free Full Text]
18. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis Circulation 2002;105:1135-1143.[Abstract/Free Full Text]
19. Moreno PR, Purushothaman KR, Fuster V, O’Connor WN. Intimomedial interface damage and adventitial inflammation is increased beneath disrupted atherosclerosis in the aortaimplications for plaque vulnerability. Circulation 2002;105:2504-2511.[Abstract/Free Full Text]
20. Moreno PR, Purushothaman KR, Fuster V, Echeverri D, Trucszczynska H, O’Connor WN. Tunica media and plaque neovascularization is increased in ruptured atherosclerotic lesions of human aortaimplications for plaque vulnerability. Circulation 2004;110:2032-2038.[Abstract/Free Full Text]
21. Kolodgie FD, Gold HK, Burke AP, et al. Intraplaque hemorrhage and progression of coronary atheroma N Engl J Med 2003;349:2316-2325.[CrossRef][Web of Science][Medline]
22. Ware JA. Too many vessels? Not enough? The wrong kind? The VEGF debate continues Nat Med 2001;7:403-404.[CrossRef][Web of Science][Medline]
23. Williams JK, Heistad DD. [The vasa vasorum of the arteries] J Mal Vasc 1996;21(Suppl C):266-269.[Web of Science][Medline]
24. Burke AP, Farb A, Malcom GT, Liang YH, Smialek J, Virmani R. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly N Engl J Med 1997;336:1276-1282.[CrossRef][Web of Science][Medline]
25. Farb A, Burke AP, Tang AL, et al. Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death Circulation 1996;93:1354-1363.[Abstract/Free Full Text]
26. Schaar JA, Muller JE, Falk E, et al. Terminology for high-risk and vulnerable coronary artery plaques. Report of a meeting on the vulnerable plaque, June 17 and 18, 2003, Santorini, Greece Eur Heart J 2004;25:1077-1082.[Abstract/Free Full Text]
27. Stary HC. Natural history and histologic classification of atherosclerotic lesionsan update. Arterioscler Thromb Vasc Biol 2000;20:1177-1178.[Free Full Text]
28. Canto JG, Shlipak MG, Rogers WJ, et al. Prevalence, clinical characteristics, and mortality among patients with myocardial infarction presenting without chest pain JAMA 2000;283:3223-3229.[Abstract/Free Full Text]
29. Sheifer SE, Manolio TA, Gersh BJ. Unrecognized myocardial infarction Ann Intern Med 2001;135:801-811.[Abstract/Free Full Text]
30. Pohl T, Seiler C, Billinger M, et al. Frequency distribution of collateral flow and factors influencing collateral channel development. Functional collateral channel measurement in 450 patients with coronary artery disease J Am Coll Cardiol 2001;38:1872-1878.[Abstract/Free Full Text]
31. Werner GS, Ferrari M, Betge S, Gastmann O, Richartz BM, Figulla HR. Collateral function in chronic total coronary occlusions is related to regional myocardial function and duration of occlusion Circulation 2001;104:2784-2790.[Abstract/Free Full Text]
32. Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM. Lessons from sudden coronary deatha comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2000;20:1262-1275.[Free Full Text]
33. Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunctiona marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 2003;23:168-175.[Abstract/Free Full Text]
34. Ignarro LJ. Experimental evidences of nitric oxide-dependent vasodilatory activity of nebivolol, a third-generation beta-blocker Blood Press Suppl 2004;1:2-16.[Medline]
35. Ignarro LJ, Napoli C. Novel features of nitric oxide, endothelial nitric oxide synthase, and atherosclerosis Curr Atheroscler Rep 2004;6:281-287.[Medline]
36. Voetsch B, Jin RC, Loscalzo J. Nitric oxide insufficiency and atherothrombosis Histochem Cell Biol 2004;122:353-367.[CrossRef][Web of Science][Medline]
37. Ravensbergen J, Ravensbergen JW, Krijger JK, Hillen B, Hoogstraten HW. Localizing role of hemodynamics in atherosclerosis in several human vertebrobasilar junction geometries Arterioscler Thromb Vasc Biol 1998;18:708-716.[Abstract/Free Full Text]
38. Nerem RM. Vascular fluid mechanics, the arterial wall, and atherosclerosis J Biomech Eng 1992;114:274-282.[Web of Science][Medline]
39. Gimbrone Jr. MA, Nagel T, Topper JN. Biomechanical activationan emerging paradigm in endothelial adhesion biology. J Clin Invest 1997;99:1809-1813.[Web of Science][Medline]
40. Traub O, Ishida T, Ishida M, Tupper JC, Berk BC. Shear stress-mediated extracellular signal-regulated kinase activation is regulated by sodium in endothelial cells. Potential role for a voltage-dependent sodium channel J Biol Chem 1999;274:20144-20150.[Abstract/Free Full Text]
41. Kunsch C, Medford RM. Oxidative stress as a regulator of gene expression in the vasculature Circ Res 1999;85:753-766.[Abstract/Free Full Text]
42. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseasesthe role of oxidant stress. Circ Res 2000;87:840-844.[Abstract/Free Full Text]
43. Malek AM, Alper SL, Izumo S. Hemodynamic shear stress and its role in atherosclerosis JAMA 1999;282:2035-2042.[Abstract/Free Full Text]
44. De Caterina R, Bourcier T, Laufs U, et al. Induction of endothelial-leukocyte interaction by interferon-gamma requires coactivation of nuclear factor- B Arterioscler Thromb Vasc Biol 2001;21:227-232.[Abstract/Free Full Text]
45. Haim M, Tanne D, Boyko V, et al. Soluble intercellular adhesion molecule-1 and long-term risk of acute coronary events in patients with chronic coronary heart disease. Data from the Bezafibrate Infarction Prevention (BIP) study J Am Coll Cardiol 2002;39:1133-1138.[Abstract/Free Full Text]
46. Dong ZM, Chapman SM, Brown AA, Frenette PS, Hynes RO, Wagner DD. The combined role of P- and E-selectins in atherosclerosis J Clin Invest 1998;102:145-152.[Web of Science][Medline]
47. Malik I, Danesh J, Whincup P, et al. Soluble adhesion molecules and prediction of coronary heart diseasea prospective study and meta-analysis. Lancet 2001;358:971-976.[CrossRef][Web of Science][Medline]
48. van der Meer IM, de Maat MP, Bots ML, et al. Inflammatory mediators and cell adhesion molecules as indicators of severity of atherosclerosisthe Rotterdam Study. Arterioscler Thromb Vasc Biol 2002;22:838-842.[Abstract/Free Full Text]
49. Steinberg DPS, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity N Engl J Med 1989;320:915-924.[Web of Science][Medline]
50. Khalil MF, Wagner WD, Goldberg IJ. Molecular interactions leading to lipoprotein retention and the initiation of atherosclerosis Arterioscler Thromb Vasc Biol 2004;24:2211-2218.[Abstract/Free Full Text]
51. Zhang Y, Zanotti I, Reilly MP, Glick JM, Rothblat GH, Rader DJ. Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo Circulation 2003;108:661-663.[Abstract/Free Full Text]
52. Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM. Antiinflammatory properties of HDL Circ Res 2004;95:764-772.[Abstract/Free Full Text]
53. Barter P. HDLa recipe for longevity. Atheroscler Suppl 2004;5:25-31.[Medline]
54. Shah PK, Kaul S, Nilsson J, Cercek B. Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteinsan idea whose time for testing is coming, part I. Circulation 2001;104:2376-2383.[Free Full Text]
55. Shah PK, Kaul S, Nilsson J, Cercek B. Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteinsan idea whose time for testing is coming, part II. Circulation 2001;104:2498-2502.[Free Full Text]
56. Badimon JJ, Badimon L, Galvez A, Dische R, Fuster V. High density lipoprotein plasma fractions inhibit aortic fatty streaks in cholesterol-fed rabbits Lab Invest 1989;60:455-461.[Web of Science][Medline]
57. Badimon JJ, Badimon L, Fuster V. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit J Clin Invest 1990;85:1234-1241.[Web of Science][Medline]
58. Ameli S, Hultgardh-Nilsson A, Cercek B, et al. Recombinant apolipoprotein A-I Milano reduces intimal thickening after balloon injury in hypercholesterolemic rabbits Circulation 1994;90:1935-1941.[Abstract/Free Full Text]
59. Shah PK, Nilsson J, Kaul S, et al. Effects of recombinant apolipoprotein A-I(Milano) on aortic atherosclerosis in apolipoprotein E-deficient mice Circulation 1998;97:780-785.[Abstract/Free Full Text]
60. Shah PK, Yano J, Reyes O, et al. High-dose recombinant apolipoprotein A-I(Milano) mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein e-deficient micepotential implications for acute plaque stabilization. Circulation 2001;103:3047-3050.[Abstract/Free Full Text]
61. Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromesa randomized controlled trial. JAMA 2003;290:2292-2300.[Abstract/Free Full Text]
62. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease N Engl J Med 2001;345:1583-1592.[CrossRef][Web of Science][Medline]
63. Cheung MC, Zhao XQ, Chait A, Albers JJ, Brown BG. Antioxidant supplements block the response of HDL to simvastatin-niacin therapy in patients with coronary artery disease and low HDL Arterioscler Thromb Vasc Biol 2001;21:1320-1326.[Abstract/Free Full Text]
64. Hansson GK, Libby P, Schonbeck U, Yan ZQ. Innate and adaptive immunity in the pathogenesis of atherosclerosis Circ Res 2002;91:281-291.[Abstract/Free Full Text]
65. Binder CJ, Chang MK, Shaw PX, et al. Innate and acquired immunity in atherogenesis Nat Med 2002;8:1218-1226.[CrossRef][Web of Science][Medline]
66. Gordon S. Pattern recognition receptorsdoubling up for the innate immune response. Cell 2002;111:927-930.[CrossRef][Web of Science][Medline]
67. Andersen HO, Holm P, Stender S, Hansen BF, Nordestgaard BG. Dose-dependent suppression of transplant arteriosclerosis in aorta-allografted, cholesterol-clamped rabbits. Suppression not eliminated by the cholesterol-raising effect of cyclosporine Arterioscler Thromb Vasc Biol 1997;17:2515-2523.[Abstract/Free Full Text]
68. Steinberg D, Witztum JL. Is the oxidative modification hypothesis relevant to human atherosclerosis? Do the antioxidant trials conducted to date refute the hypothesis? Circulation 2002;105:2107-2111.[Free Full Text]
69. Hansson GK. Immune mechanisms in atherosclerosis Arterioscler Thromb Vasc Biol 2001;21:1876-1890.[Abstract/Free Full Text]
70. Rosenfeld ME. Leukocyte recruitment into developing atherosclerotic lesionsthe complex interaction between multiple molecules keeps getting more complex. Arterioscler Thromb Vasc Biol 2002;22:361-363.[Free Full Text]
71. Okamura Y, Watari M, Jerud ES, et al. The extra domain A of fibronectin activates Toll-like receptor 4 J Biol Chem 2001;276:10229-10233.[Abstract/Free Full Text]
72. Tsan MF, Gao B. Cytokine function of heat shock proteins Am J Physiol Cell Physiol 2004;286:C739-C744.[Abstract/Free Full Text]
73. Triantafilou M, Triantafilou K. Heat-shock protein 70 and heat-shock protein 90 associate with Toll-like receptor 4 in response to bacterial lipopolysaccharide Biochem Soc Trans 2004;32:636-639.[CrossRef][Web of Science][Medline]
74. Vink A, Schoneveld AH, van der Meer JJ, et al. In vivo evidence for a role of Toll-like receptor 4 in the development of intimal lesions Circulation 2002;106:1985-1990.[Abstract/Free Full Text]
75. Pasterkamp G, Van Keulen JK, De Kleijn DP. Role of Toll-like receptor 4 in the initiation and progression of atherosclerotic disease Eur J Clin Invest 2004;34:328-334.[CrossRef][Web of Science][Medline]
76. Hollestelle SC, De Vries MR, Van Keulen JK, et al. Toll-like receptor 4 is involved in outward arterial remodeling Circulation 2004;109:393-398.[Abstract/Free Full Text]
77. Nilsson J, Hansson GK, Shah PK. Immunomodulation of atherosclerosis. Implications for vaccine development Arterioscler Thromb Vasc Biol 2005;25:1-11.[Free Full Text]
78. Fitzpatrick LA, Severson A, Edwards WD, Ingram RT. Diffuse calcification in human coronary arteries. Association of osteopontin with atherosclerosis J Clin Invest 1994;94:1597-1604.[Web of Science][Medline]
79. O’Brien ER, Garvin MR, Stewart DK, et al. Osteopontin is synthesized by macrophage, smooth muscle, and endothelial cells in primary and restenotic human coronary atherosclerotic plaques Arterioscler Thromb 1994;14:1648-1656.[Abstract/Free Full Text]
80. Ikeda T, Shirasawa T, Esaki Y, Yoshiki S, Hirokawa K. Osteopontin mRNA is expressed by smooth muscle-derived foam cells in human atherosclerotic lesions of the aorta J Clin Invest 1993;92:2814-2820.[Web of Science][Medline]
81. Towler DA, Bidder M, Latifi T, Coleman T, Semenkovich CF. Diet-induced diabetes activates an osteogenic gene regulatory program in the aortas of low density lipoprotein receptor-deficient mice J Biol Chem 1998;273:30427-30434.[Abstract/Free Full Text]
82. Liaw L, Lombardi DM, Almeida MM, Schwartz SM, deBlois D, Giachelli CM. Neutralizing antibodies directed against osteopontin inhibit rat carotid neointimal thickening after endothelial denudation Arterioscler Thromb Vasc Biol 1997;17:188-193.[Abstract/Free Full Text]
83. Liaw L, Almeida M, Hart CE, Schwartz SM, Giachelli CM. Osteopontin promotes vascular cell adhesion and spreading and is chemotactic for smooth muscle cells in vitro Circ Res 1994;74:214-224.[Abstract/Free Full Text]
84. Takemoto M, Yokote K, Yamazaki M, et al. Enhanced expression of osteopontin by high glucose. Involvement of osteopontin in diabetic macroangiopathy Ann N Y Acad Sci 2000;902:357-363.[CrossRef][Web of Science][Medline]
85. Takemoto M, Yokote K, Nishimura M, et al. Enhanced expression of osteopontin in human diabetic artery and analysis of its functional role in accelerated atherogenesis Arterioscler Thromb Vasc Biol 2000;20:624-628.[Abstract/Free Full Text]
86. Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ. Compensatory enlargement of human atherosclerotic coronary arteries N Engl J Med 1987;316:1371-1375.[Web of Science][Medline]
87. Ward MR, Pasterkamp G, Yeung AC, Borst C. Arterial remodeling. Mechanisms and clinical implications Circulation 2000;102:1186-1191.[Free Full Text]
88. Tronc F, Mallat Z, Lehoux S, Wassef M, Esposito B, Tedgui A. Role of matrix metalloproteinases in blood flow-induced arterial enlargementinteraction with NO. Arterioscler Thromb Vasc Biol 2000;20:E120-E126.[Web of Science]
89. Burke AP, Kolodgie FD, Farb A, Weber D, Virmani R. Morphological predictors of arterial remodeling in coronary atherosclerosis Circulation 2002;105:297-303.[Abstract/Free Full Text]
90. Polverini PJ, Cotran PS, Gimbrone Jr. MA, Unanue ER. Activated macrophages induce vascular proliferation Nature 1977;269:804-806.[CrossRef][Medline]
91. Lee WS, Jain MK, Arkonac BM, et al. Thy-1, a novel marker for angiogenesis upregulated by inflammatory cytokines Circ Res 1998;82:845-851.[Abstract/Free Full Text]
92. Herrmann J, Lerman LO, Rodriguez-Porcel M, et al. Coronary vasa vasorum neovascularization precedes epicardial endothelial dysfunction in experimental hypercholesterolemia Cardiovasc Res 2001;51:762-766.[Abstract/Free Full Text]
93. Wolinsky H, Glagov S. Nature of species differences in the medial distribution of aortic vasa vasorum in mammals Circ Res 1967;20:409-421.[Abstract/Free Full Text]
94. Barger AC, Beeuwkes 3rd R, Lainey LL, Silverman KJ. Hypothesis: vasa vasorum and neovascularization of human coronary arteries. A possible role in the pathophysiology of atherosclerosis N Engl J Med 1984;310:175-177.[Web of Science][Medline]
95. Heistad DD, Marcus ML. Role of vasa vasorum in nourishment of the aorta Blood Vessels 1979;16:225-238.[Web of Science][Medline]
96. Williams JK, Armstrong ML, Heistad DD. Vasa vasorum in atherosclerotic coronary arteriesresponses to vasoactive stimuli and regression of atherosclerosis. Circ Res 1988;62:515-523.[Abstract/Free Full Text]
97. Barker SG, Talbert A, Cottam S, Baskerville PA, Martin JF. Arterial intimal hyperplasia after occlusion of the adventitial vasa vasorum in the pig Arterioscler Thromb 1993;13:70-77.[Abstract/Free Full Text]
98. Barker SG, Tilling LC, Miller GC, et al. The adventitia and atherogenesisremoval initiates intimal proliferation in the rabbit which regresses on generation of a ‘neoadventitia. ’ Atherosclerosis 1994;105:131-144.
99. De Meyer GR, Van Put DJ, Kockx MM, et al. Possible mechanisms of collar-induced intimal thickening Arterioscler Thromb Vasc Biol 1997;17:1924-1930.[Abstract/Free Full Text]
100. Moulton KS, Heller E, Konerding MA, Flynn E, Palinski W, Folkman J. Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice Circulation 1999;99:1726-1732.[Abstract/Free Full Text]
101. Moulton KS, Vakili K, Zurakowski D, et al. Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis Proc Natl Acad Sci U S A 2003;100:4736-4741.[Abstract/Free Full Text]
102. Kwon HM, Sangiorgi G, Ritman EL, et al. Enhanced coronary vasa vasorum neovascularization in experimental hypercholesterolemia J Clin Invest 1998;101:1551-1556.[Web of Science][Medline]
103. Scotland RS, Vallance PJ, Ahluwalia A. Endogenous factors involved in regulation of tone of arterial vasa vasorumimplications for conduit vessel physiology. Cardiovasc Res 2000;46:403-411.[Abstract/Free Full Text]
104. Kumamoto M, Nakashima Y, Sueishi K. Intimal neovascularization in human coronary atherosclerosisits origin and pathophysiological significance. Hum Pathol 1995;26:450-456.[CrossRef][Web of Science][Medline]
105. Fleiner M, Kummer M, Mirlacher M, et al. Arterial neovascularization and inflammation in vulnerable patientsearly and late signs of symptomatic atherosclerosis. Circulation 2004;110:2843-2850.[Abstract/Free Full Text]
106. Purushothaman KR, Echeverri D, Fuster V, O’Connor W, Moreno PR. Neovascularization, inflammation and intra-plaque hemorrhage are increased in advanced human atherosclerosis from patients with diabetes mellitus(abstr) Circulation 2003;108:459.
107. Purushothaman KR, O’Connor WN, Echeverri D, Amadi C, Badimon JJ, Fuster V, Moreno PR. Ruptured diabetic atherosclerotic plaques have more inflammation and neovascularization than ruptured plaques from patients without diabetes(abstr) J Am Coll Cardiol 2004;43(Suppl A):496A.
108. Purushothaman KR, O’Connor WN, Echeverri D, Amadi C, Sharma SK, Fuster V, Moreno PR. Atherosclerotic plaque inflammation is associated with increased intimo-medial neovascularization(abstr) J Am Coll Cardiol 2004;43(Suppl A):477A.
109. Moreno PR, Purushothaman KR, O’Connor WN, Kini A, Sirol M, Sharma SK, Fuster V. Microvessel sprouting, red blood cell extravasation, and peri-vascular inflammation is increased in plaques from patients with diabetes mellitus(abstr) J Am Coll Cardiol 2005;45(Suppl A):430A.
110. Purushothaman KR, Moreno PR, O’Connor WN, Kini AS, Sharma SK, Fuster V. Histological evidence for atherosclerotic neovascularization as a pathway for macrophage infiltration in diabetes mellitus(abstr) J Am Coll Cardiol 2005;45(Suppl A):439A.[CrossRef]
111. Moreno PR, Purushothaman KR, Fuster V, et al. Plaque neovascularization is increased in ruptured atherosclerotic lesions of human aortaimplications for plaque vulnerability. Circulation 2004;110:2032-2038.[Abstract/Free Full Text]
112. Moreno PR, Purushothaman KR, O’Connor WN, Kini AS, Sirol M, Sharma SK, Fuster V. Increased inflammation and neovascularization in diabetic atherosclerosis is no longer present in fibrocalcific plaquesa marker of stabilization?. (abstr) J Am Coll Cardiol 2005;45(Suppl A):402A.
113. Corti R, Fayad ZA, Fuster V, et al. Effects of lipid-lowering by simvastatin on human atherosclerotic lesionsa longitudinal study by high-resolution, noninvasive magnetic resonance imaging. Circulation 2001;104:249-252.[Abstract/Free Full Text]
114. Davies MJ, Richardson PD, Woolf N, Katz DR, Mann J. Risk of thrombosis in human atherosclerotic plaquesrole of extracellular lipid, macrophage, and smooth muscle cell content. Br Heart J 1993;69:377-381.[Abstract/Free Full Text]
115. Kaartinen M, Penttila A, Kovanen PT. Accumulation of activated mast cells in the shoulder region of human coronary atheroma, the predilection site of atheromatous rupture Circulation 1994;90:1669-1678.[Abstract/Free Full Text]
116. Shah PK, Falk E, Badimon JJ, et al. Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading metalloproteinases and implications for plaque rupture Circulation 1995;92:1565-1569.[Web of Science][Medline]
117. Shah PK, Galis ZS. Matrix metalloproteinase hypothesis of plaque ruptureplayers keep piling up but questions remain. Circulation 2001;104:1878-1880.[Free Full Text]
118. Sukhova GK, Schonbeck U, Rabkin E, et al. Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques Circulation 1999;99:2503-2509.[Abstract/Free Full Text]
119. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesisthe good, the bad, and the ugly. Circ Res 2002;90:251-262.[Abstract/Free Full Text]
120. Zureik M, Robert L, Courbon D, Touboul PJ, Bizbiz L, Ducimetiere P. Serum elastase activity, serum elastase inhibitors, and occurrence of carotid atherosclerotic plaquesthe Etude sur le Vieillissement Arteriel (EVA) study. Circulation 2002;105:2638-2645.[Abstract/Free Full Text]
121. Lindsey ML, Gannon J, Aikawa M, et al. Selective matrix metalloproteinase inhibition reduces left ventricular remodeling but does not inhibit angiogenesis after myocardial infarction Circulation 2002;105:753-758.[Abstract/Free Full Text]
122. Abou-Raya S, Naim A, Marzouk S. Cardiac matrix remodeling in congestive heart failurethe role of matrix metalloproteinases. Clin Invest Med 2004;27:93-100.[Web of Science][Medline]
123. Polyakova V, Hein S, Kostin S, Ziegelhoeffer T, Schaper J. Matrix metalloproteinases and their tissue inhibitors in pressure-overloaded human myocardium during heart failure progression J Am Coll Cardiol 2004;44:1609-1618.[Abstract/Free Full Text]
124. Shah BH, Catt KJ. Matrix metalloproteinase-dependent EGF receptor activation in hypertension and left ventricular hypertrophy Trends Endocrinol Metab 2004;15:241-243.[CrossRef][Web of Science][Medline]
125. Young DA, Gavrilov S, Pennington CJ, et al. Expression of metalloproteinases and inhibitors in the differentiation of P19CL6 cells into cardiac myocytes Biochem Biophys Res Commun 2004;322:759-765.[CrossRef][Web of Science][Medline]
126. Rabkin-Aikawa E, Farber M, Aikawa M, Schoen FJ. Dynamic and reversible changes of interstitial cell phenotype during remodeling of cardiac valves J Heart Valve Dis 2004;13:841-847.[Web of Science][Medline]
127. Skalen K, Gustafsson M, Rydberg EK, et al. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis Nature 2002;417:750-754.[CrossRef][Medline]
128. Camejo G. Hydrolytic enzymes released from resident macrophages and located in the intima extracellular matrix as agents that modify retained apolipoprotein B lipoproteins Arterioscler Thromb Vasc Biol 2003;23:1312-1313.[Free Full Text]
129. Hakala JK, Oksjoki R, Laine P, et al. Lysosomal enzymes are released from cultured human macrophages, hydrolyze LDL in vitro, and are present extracellularly in human atherosclerotic lesions Arterioscler Thromb Vasc Biol 2003;23:1430-1436.[Abstract/Free Full Text]
130. Seshiah PN, Kereiakes DJ, Vasudevan SS, et al. Activated monocytes induce smooth muscle cell deathrole of macrophage colony-stimulating factor and cell contact. Circulation 2002;105:174-180.[Abstract/Free Full Text]
131. Mallat Z, Hugel B, Ohan J, Leseche G, Freyssinet JM, Tedgui A. Shed membrane microparticles with procoagulant potential in human atherosclerotic plaquesa role for apoptosis in plaque thrombogenicity. Circulation 1999;99:348-353.[Abstract/Free Full Text]
132. Hutter R, Valdiviezo C, Sauter BV, et al. Caspase-3 and tissue factor expression in lipid-rich plaque macrophagesevidence for apoptosis as link between inflammation and atherothrombosis. Circulation 2004;109:2001-2008.[Abstract/Free Full Text]
133. Hutter R, Badimon JJ, Sauter BV, Fallon JT, Fuster V. Arterial injury in ApoII wild type mice. Evidence for macrophage apoptosis as a mechanism regulating tissue-factor expression and plaque growth(abstr) J Am Coll Cardiol 2002;39(Suppl A):257A.
134. Mallat Z, Tedgui A. Current perspective on the role of apoptosis in atherothrombotic disease Circ Res 2001;88:998-1003.[Abstract/Free Full Text]
135. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. Parts 1 and 2 N Engl J Med 1992;326:242-250and 310–8.[Web of Science][Medline]
136. Theroux P, Fuster V. Acute coronary syndromesunstable angina and non–Q-wave myocardial infarction. Circulation 1998;97:1195-1206.[Free Full Text]
137. Fuster V. Mechanisms leading to myocardial infarctioninsights from studies of vascular biology. Circulation 1994;90:2126-2146.[Abstract/Free Full Text]
138. Toschi V, Gallo R, Lettino M, et al. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques Circulation 1997;95:594-599.[Abstract/Free Full Text]
139. Fernandez-Ortiz A, Badimon JJ, Falk E, et al. Characterization of the relative thrombogenicity of atherosclerotic plaque componentsimplications for consequences of plaque rupture. J Am Coll Cardiol 1994;23:1562-1569.[Abstract]
140. Marmur JD, Thiruvikraman SV, Fyfe BS, et al. Identification of active tissue factor in human coronary atheroma Circulation 1996;94:1226-1232.[Abstract/Free Full Text]
141. Rauch U, Osende JI, Fuster V, Badimon JJ, Fayad Z, Chesebro JH. Thrombus formation on atherosclerotic plaquespathogenesis and clinical consequences. Ann Intern Med 2001;134:224-238.[Abstract/Free Full Text]
142. Rauch U, Bonderman D, Bohrmann B, et al. Transfer of tissue factor from leukocytes to platelets is mediated by CD15 and tissue factor Blood 2000;96:170-175.[Abstract/Free Full Text]
143. Meyer BJ, Badimon JJ, Mailhac A, et al. Inhibition of growth of thrombus on fresh mural thrombus. Targeting optimal therapy Circulation 1994;90:2432-2438.[Abstract/Free Full Text]
144. Meyer BJ, Badimon JJ, Chesebro JH, Fallon JT, Fuster V, Badimon L. Dissolution of mural thrombus by specific thrombin inhibition with r-hirudincomparison with heparin and aspirin. Circulation 1998;97:681-685.[Abstract/Free Full Text]
145. Nemerson Y. Tissue factor and hemostasis Blood 1988;71:1-8.[Free Full Text]
146. Banner DW, D’Arcy A, Chene C, et al. The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor Nature 1996;380:41-46.[CrossRef][Medline]
147. Moreno PR, Bernardi VH, Lopez-Cuellar J, et al. Macrophages, smooth muscle cells, and tissue factor in unstable angina. Implications for cell-mediated thrombogenicity in acute coronary syndromes Circulation 1996;94:3090-3097.[Abstract/Free Full Text]
148. Hutter R, Sauter BV, Fallon JT, Fuster V, Badimon JJ. Macrophages and vascular stellate cells in human carotid plaques are prone to apoptosis and tissue factor expression(abstr) J Am Coll Cardiol 2001;38(Suppl A):288A.[CrossRef]
149. Badimon JJ, Lettino M, Toschi V, et al. Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaqueseffects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions. Circulation 1999;99:1780-1787.[Abstract/Free Full Text]
150. Roque M, Reis ED, Fuster V, et al. Inhibition of tissue factor reduces thrombus formation and intimal hyperplasia after porcine coronary angioplasty J Am Coll Cardiol 2000;36:2303-2310.[Abstract/Free Full Text]
151. Shah PK. Reduced tissue factor pathway inhibitor-1 after pharmacological thrombolysisan epiphenomenon or potential culprit in re-thrombosis?. Circulation 2002;105:270-271.[Free Full Text]
152. Ott I, Malcouvier V, Schomig A, Neumann FJ. Proteolysis of tissue factor pathway inhibitor-1 by thrombolysis in acute myocardial infarction Circulation 2002;105:279-281.[Abstract/Free Full Text]
153. Kato H. Regulation of functions of vascular wall cells by tissue factor pathway inhibitorbasic and clinical aspects. Arterioscler Thromb Vasc Biol 2002;22:539-548.[Abstract/Free Full Text]
154. Badimon L, Badimon JJ. Mechanisms of arterial thrombosis in nonparallel streamlines: platelet thrombi grow on the apex of stenotic severely injured vessel wall. Experimental study in the pig model J Clin Invest 1989;84:1134-1144.[Web of Science][Medline]
155. Frojmovic M, Nash G, Diamond SL. Definitions in biorheology: cell aggregation and cell adhesion in flow. Recommendation of the Scientific Subcommittee on Biorheology of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis Thromb Haemost 2002;87:771.[Web of Science][Medline]
156. Willerson JT, Golino P, Eidt J, Campbell WB, Buja LM. Specific platelet mediators and unstable coronary artery lesions. Experimental evidence and potential clinical implications Circulation 1989;80:198-205.[Abstract/Free Full Text]
157. Maseri A, L’Abbate A, Baroldi G, et al. Coronary vasospasm as a possible cause of myocardial infarction. A conclusion derived from the study of "preinfarction" angina N Engl J Med 1978;299:1271-1277.[Web of Science][Medline]
158. Kullo IJ, Edwards WD, Schwartz RS. Vulnerable plaquepathobiology and clinical implications. Ann Intern Med 1998;129:1050-1060.[Abstract/Free Full Text]
159. Kullo IJ, Gau GT, Tajik AJ. Novel risk factors for atherosclerosis Mayo Clin Proc 2000;75:369-380.[Abstract/Free Full Text]
160. Salomaa V, Rasi V, Kulathinal S, et al. Hemostatic factors as predictors of coronary events and total mortalitythe FINRISK ‘92 Hemostasis study. Arterioscler Thromb Vasc Biol 2002;22:353-358.[Abstract/Free Full Text]
161. Edelberg JM, Christie PD, Rosenberg RD. Regulation of vascular bed-specific prothrombotic potential Circ Res 2001;89:117-124.[Abstract/Free Full Text]
162. Edgington TS. So what is critically lacking with coronary atherosclerotic plaques? Perhaps the antithrombotic control Am J Pathol 2001;159:795-796.[Web of Science][Medline]
163. Dangas G, Badimon JJ, Smith DA, et al. Pravastatin therapy in hyperlipidemiaeffects on thrombus formation and the systemic hemostatic profile. J Am Coll Cardiol 1999;33:1294-1304.[Abstract/Free Full Text]
164. Rauch U, Osende JI, Chesebro JH, et al. Statins and cardiovascular diseasesthe multiple effects of lipid-lowering therapy by statins. Atherosclerosis 2000;153:181-189.[CrossRef][Web of Science][Medline]
165. Badimon L, Martinez-Gonzalez J, Royo T, Lassila R, Badimon JJ. A sudden increase in plasma epinephrine levels transiently enhances platelet deposition on severely damaged arterial wall—studies in a porcine model Thromb Haemost 1999;82:1736-1742.[Web of Science][Medline]
166. Miller GJ. Hemostasis and cardiovascular risk. The British and European experience Arch Pathol Lab Med 1992;116:1318-1321.[Web of Science][Medline]
167. Muller JE, Kaufmann PG, Luepker RV, Weisfeldt ML, Deedwania PC, Willerson JT. Mechanisms precipitating acute cardiac events: review and recommendations of an NHLBI workshop. National Heart, Lung, and Blood Institute. Mechanisms Precipitating Acute Cardiac Events Participants Circulation 1997;96:3233-3239.[Free Full Text]
168. Meigs JB, Mittleman MA, Nathan DM, et al. Hyperinsulinemia, hyperglycemia, and impaired hemostasisthe Framingham Offspring Study. JAMA 2000;283:221-228.[Abstract/Free Full Text]
169. Rauch U, Ziegler D, Piolot R, et al. Platelet activation in diabetic cardiovascular autonomic neuropathy Diabet Med 1999;16:848-852.[CrossRef][Web of Science][Medline]
170. Sambola A, Osende J, Hathcock J, et al. Role of risk factors in the modulation of tissue factor activity and blood thrombogenicity Circulation 2003;107:973-977.[Abstract/Free Full Text]
171. Osende JI, Badimon JJ, Fuster V, et al. Blood thrombogenicity in type 2 diabetes mellitus patients is associated with glycemic control J Am Coll Cardiol 2001;38:1307-1312.[Abstract/Free Full Text]
172. Tschoepe D, Rauch U, Schwippert B. Platelet-leukocyte-cross-talk in diabetes mellitus Horm Metab Res 1997;29:631-635.[Web of Science][Medline]
173. Rauch U, Crandall J, Osende JI, et al. Increased thrombus formation relates to ambient blood glucose and leukocyte count in diabetes mellitus type 2 Am J Cardiol 2000;86:246-249.[CrossRef][Web of Science][Medline]
174. Kallen J, Welzenbach K, Ramage P, et al. Structural basis for LFA-1 inhibition upon lovastatin binding to the CD11a I-domain J Mol Biol 1999;292:1-9.[CrossRef][Web of Science][Medline]
175. Frenette PS. Locking a leukocyte integrin with statins N Engl J Med 2001;345:1419-1421.[CrossRef][Web of Science][Medline]
176. Walter DH, Rittig K, Bahlmann FH, et al. Statin therapy accelerates reendothelializationa novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation 2002;105:3017-3024.[Abstract/Free Full Text]
177. Soejima H, Ogawa H, Yasue H, et al. Heightened tissue factor associated with tissue factor pathway inhibitor and prognosis in patients with unstable angina Circulation 1999;99:2908-2913.[Abstract/Free Full Text]
178. Gando S, Nanzaki S, Sasaki S, Kemmotsu O. Significant correlations between tissue factor and thrombin markers in trauma and septic patients with disseminated intravascular coagulation Thromb Haemost 1998;79:1111-1115.[Web of Science][Medline]
179. Rosenberg RD, Aird WC. Vascular bed-specific hemostasis and hypercoagulable states N Engl J Med 1999;340:1555-1564.[CrossRef][Web of Science][Medline]
180. Soejima H, Ogawa H, Yasue H, et al. Angiotensin-converting enzyme inhibition reduces monocyte chemoattractant protein-1 and tissue factor levels in patients with myocardial infarction J Am Coll Cardiol 1999;34:983-988.[Abstract/Free Full Text]
181. Saito Y, Wada H, Yamamuro M, et al. Changes of plasma hemostatic markers during percutaneous transluminal coronary angioplasty in patients with chronic coronary artery disease Am J Hematol 1999;61:238-242.[CrossRef][Web of Science][Medline]
182. Hugel B, Socie G, Vu T, et al. Elevated levels of circulating procoagulant microparticles in patients with paroxysmal nocturnal hemoglobinuria and aplastic anemia Blood 1999;93:3451-3456.[Abstract/Free Full Text]
183. Giesen PL, Rauch U, Bohrmann B, et al. Blood-borne tissue factoranother view of thrombosis. Proc Natl Acad Sci U S A 1999;96:2311-2315.[Abstract/Free Full Text]
184. Lewis JC, Bennett-Cain AL, DeMars CS, et al. Procoagulant activity after exposure of monocyte-derived macrophages to minimally oxidized low density lipoprotein. Co-localization of tissue factor antigen and nascent fibrin fibers at the cell surface Am J Pathol 1995;147:1029-1040.[Web of Science][Medline]
185. Munford RS. Statins and the acute-phase response N Engl J Med 2001;344:2016-2018.[CrossRef][Web of Science][Medline]
186. Blake GJ, Ridker PM. Novel clinical markers of vascular wall inflammation Circ Res 2001;89:763-771.[Abstract/Free Full Text]
187. Ridker PM, Rifai N, Clearfield M, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events N Engl J Med 2001;344:1959-1965.[CrossRef][Web of Science][Medline]
188. Bickel C, Rupprecht HJ, Blankenberg S, et al. Relation of markers of inflammation (C-reactive protein, fibrinogen, von Willebrand factor, and leukocyte count) and statin therapy to long-term mortality in patients with angiographically proven coronary artery disease Am J Cardiol 2002;89:901-908.[CrossRef][Web of Science][Medline]
189. Burke AP, Tracy RP, Kolodgie F, et al. Elevated C-reactive protein values and atherosclerosis in sudden coronary deathassociation with different pathologies. Circulation 2002;105:2019-2023.[Abstract/Free Full Text]
190. Zwaka TP, Hombach V, Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophagesimplications for atherosclerosis. Circulation 2001;103:1194-1197.[Abstract/Free Full Text]
191. Torzewski M, Rist C, Mortensen RF, et al. C-reactive protein in the arterial intimarole of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol 2000;20:2094-2099.[Abstract/Free Full Text]
192. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells Circulation 2000;102:2165-2168.[Abstract/Free Full Text]
193. Schonbeck U, Libby P. CD40 signaling and plaque instability Circ Res 2001;89:1092-1103.[Abstract/Free Full Text]
194. Schonbeck U, Varo N, Libby P, Buring J, Ridker PM. Soluble CD40L and cardiovascular risk in women Circulation 2001;104:2266-2268.[Abstract/Free Full Text]
195. Glagov S, Zarins C, Giddens DP, Ku DN. Hemodynamics and atherosclerosis. Insights and perspectives gained from studies of human arteries Arch Pathol Lab Med 1988;112:1018-1031.[Web of Science][Medline]
196. Toussaint JF, LaMuraglia GM, Southern JF, Fuster V, Kantor HL. Magnetic resonance images lipid, fibrous, calcified, hemorrhagic, and thrombotic components of human atherosclerosis in vivo Circulation 1996;94:932-938.[Abstract/Free Full Text]
197. Carr S, Farb A, Pearce WH, Virmani R, Yao JS. Atherosclerotic plaque rupture in symptomatic carotid artery stenosis J Vasc Surg 1996;23:755-765.[CrossRef][Web of Science][Medline]
198. Virmani R, Narula J, Farb A. When neoangiogenesis ricochets Am Heart J 1998;136:937-939.[CrossRef][Web of Science][Medline]
199. Yuan C, Mitsumori LM, Ferguson MS, et al. In vivo accuracy of multispectral magnetic resonance imaging for identifying lipid-rich necrotic cores and intraplaque hemorrhage in advanced human carotid plaques Circulation 2001;104:2051-2056.[Abstract/Free Full Text]
200. Yuan C, Zhang SH, Polissar NL, et al. Identification of fibrous cap rupture with magnetic resonance imaging is highly associated with recent transient ischemic attack or stroke Circulation 2002;105:181-185.[Abstract/Free Full Text]
201. Milei J, Parodi JC, Alonso GF, Barone A, Grana D, Matturri L. Carotid rupture and intraplaque hemorrhageimmunophenotype and role of cells involved. Am Heart J 1998;136:1096-1105.[CrossRef][Web of Science][Medline]
202. Spagnoli LG, Mauriello A, Sangiorgi G, et al. Extracranial thrombotically active carotid plaque as a risk factor for ischemic stroke JAMA 2004;292:1845-1852.[Abstract/Free Full Text]
203. Ouriel K. Peripheral arterial disease Lancet 2001;358:1257-1264.[CrossRef][Web of Science][Medline]
204. Jackson MR, Clagett GP. Antithrombotic therapy in peripheral arterial occlusive disease Chest 2001;119:283S-299S.[Web of Science][Medline]
205. Schmieder FA, Comerota AJ. Intermittent claudicationmagnitude of the problem, patient evaluation, and therapeutic strategies. Am J Cardiol 2001;87:3-13D.
206. Dieter RS, Chu WW, Pacanowski Jr. JP, McBride PE, Tanke TE. The significance of lower extremity peripheral arterial disease Clin Cardiol 2002;25:3-10.[Web of Science][Medline]
207. Faxon DP, Fuster V, Libby P, et al. Atherosclerotic Vascular Disease Conference: Writing Group III: pathophysiology Circulation 2004;109:2617-2625.[Free Full Text]
This article has been cited by other articles:
|
|
|
|
 
D. E. Montgomery, J. J. Puthumana, J. M. Fox, and K. O. Ogunyankin
Global longitudinal strain aids the detection of non-obstructive coronary artery disease in the resting echocardiogram
Eur Heart J Cardiovasc Imaging,
December 13, 2011;
(2011)
jer282v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Puig, J. Yuan, S. Stepaniants, R. Zieba, E. Zycband, M. Morris, S. Coulter, X. Yu, J. Menke, J. Woods, et al.
A Gene Expression Signature That Classifies Human Atherosclerotic Plaque by Relative Inflammation Status
Circ Cardiovasc Genet,
December 1, 2011;
4(6):
595 - 604.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. R. Moreno, L. Astudillo, S. Elmariah, K. R. Purushothaman, M. Purushothaman, P. A. Lento, S. K. Sharma, V. Fuster, and D. H. Adams
Increased macrophage infiltration and neovascularization in congenital bicuspid aortic valve stenosis
J. Thorac. Cardiovasc. Surg.,
October 1, 2011;
142(4):
895 - 901.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Vucic, S. D. Dickson, C. Calcagno, J. H. F. Rudd, E. Moshier, K. Hayashi, J. S. Mounessa, M. Roytman, M. J. Moon, J. Lin, et al.
Pioglitazone Modulates Vascular Inflammation in Atherosclerotic Rabbits: Noninvasive Assessment With FDG-PET-CT and Dynamic Contrast-Enhanced MR Imaging
J. Am. Coll. Cardiol. Img.,
October 1, 2011;
4(10):
1100 - 1109.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-H. Buhk, A.-K. Finck-Wedel, R. Buchert, P. Bannas, B. Schnackenburg, F. U. Beil, G. Adam, and C. Weber
Screening for atherosclerotic plaques in the abdominal aorta in high-risk patients with multicontrast-weighted MRI: a prospective study at 3.0 and 1.5 tesla
Br. J. Radiol.,
October 1, 2011;
84(1006):
883 - 889.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. F. D. Mahmood, I. Jguirim-Souissi, E.-H. Khadija, N. Blondeau, V. Diderot, S. Amrani, M.-N. Slimane, T. Syrovets, T. Simmet, and M. Rouis
Peroxisome Proliferator-activated Receptor {gamma} Induces Apoptosis and Inhibits Autophagy of Human Monocyte-derived Macrophages via Induction of Cathepsin L: POTENTIAL ROLE IN ATHEROSCLEROSIS
J. Biol. Chem.,
August 19, 2011;
286(33):
28858 - 28866.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. S. Kristensen, K. F. Kofoed, J. T. Kuhl, W. B. Nielsen, M. B. Nielsen, and H. Kelbaek
Prognostic Implications of Nonobstructive Coronary Plaques in Patients With Non-ST-Segment Elevation Myocardial Infarction: A Multidetector Computed Tomography Study
J. Am. Coll. Cardiol.,
July 26, 2011;
58(5):
502 - 509.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. Raval, M. E. Harinstein, A. I. Skaro, A. Erdogan, A. M. DeWolf, S. J. Shah, O. K. Fix, N. Kay, M. I. Abecassis, M. Gheorghiade, et al.
Cardiovascular Risk Assessment of the Liver Transplant Candidate
J. Am. Coll. Cardiol.,
July 12, 2011;
58(3):
223 - 231.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Hyafil, E. Vucic, J.-C. Cornily, R. Sharma, V. Amirbekian, F. Blackwell, E. Lancelot, C. Corot, V. Fuster, Z. S. Galis, et al.
Monitoring of arterial wall remodelling in atherosclerotic rabbits with a magnetic resonance imaging contrast agent binding to matrix metalloproteinases
Eur. Heart J.,
June 2, 2011;
32(12):
1561 - 1571.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Yonetsu, T. Kakuta, T. Lee, K. Takahashi, N. Kawaguchi, G. Yamamoto, K. Koura, K. Hishikari, Y. Iesaka, H. Fujiwara, et al.
In vivo critical fibrous cap thickness for rupture-prone coronary plaques assessed by optical coherence tomography
Eur. Heart J.,
May 2, 2011;
32(10):
1251 - 1259.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K.-R. Purushothaman, M. Purushothaman, P. Muntner, P. A. Lento, W. N. O'Connor, S. K. Sharma, V. Fuster, and P. R. Moreno
Inflammation, neovascularization and intra-plaque hemorrhage are associated with increased reparative collagen content: Implication for plaque progression in diabetic atherosclerosis
Vascular Medicine,
April 1, 2011;
16(2):
103 - 108.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. L. Ferreiro and D. J. Angiolillo
Diabetes and Antiplatelet Therapy in Acute Coronary Syndrome
Circulation,
February 22, 2011;
123(7):
798 - 813.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. W. Leeuwis, T. Q. Nguyen, M. G. J. Theunissen, W. Peeters, R. Goldschmeding, G. Pasterkamp, and A. Vink
Connective Tissue Growth Factor Is Associated With a Stable Atherosclerotic Plaque Phenotype and Is Involved in Plaque Stabilization After Stroke
Stroke,
December 1, 2010;
41(12):
2979 - 2981.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Swahn, J. Alfredsson, and S. Sederholm Lawesson
Chapter 48 Gender considerations in acute coronary syndromes
The ESC Textbook of Acute and Intensive Cardiac Care,
December 1, 2010;
1(1):
med-9780199584314-chapter - med-9780199584314-chapter.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Elmariah, J. A. C. Delaney, K. D. O'Brien, M. J. Budoff, J. Vogel-Claussen, V. Fuster, R. A. Kronmal, and J. L. Halperin
Bisphosphonate Use and Prevalence of Valvular and Vascular Calcification in Women: MESA (The Multi-Ethnic Study of Atherosclerosis)
J. Am. Coll. Cardiol.,
November 16, 2010;
56(21):
1752 - 1759.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Hur, J. Park, Y. J. Kim, H.-J. Lee, H. S. Shim, K. O. Choe, and B. W. Choi
Use of Contrast Enhancement and High-Resolution 3D Black-Blood MRI to Identify Inflammation in Atherosclerosis
J. Am. Coll. Cardiol. Img.,
November 1, 2010;
3(11):
1127 - 1135.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. J. Shaw, P. W. F. Wilson, R. Hachamovitch, R. C. Hendel, S. Borges-Neto, and D. S. Berman
Improved Near-Term Coronary Artery Disease Risk Classification With Gated Stress Myocardial Perfusion SPECT
J. Am. Coll. Cardiol. Img.,
November 1, 2010;
3(11):
1139 - 1148.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. K. Wali
Aspirin and the Prevention of Cardiovascular Disease in Chronic Kidney Disease: Time to Move Forward?
J. Am. Coll. Cardiol.,
September 14, 2010;
56(12):
966 - 968.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. L. Walton, M. Leja, K. C. Vickers, M. Estevez-Fernandez, A. Sanguino, E. Wang, F. J. Clubb Jr, J. Morrisett, and G. Lopez-Berestein
Delivery of negatively charged liposomes into the atheromas of Watanabe heritable hyperlipidemic rabbits
Vascular Medicine,
August 1, 2010;
15(4):
307 - 313.
[Abstract]
[PDF]
|
|
|
|
|
|
|
V. Fuster and S. Bansilal
Promoting Cardiovascular and Cerebrovascular Health
Stroke,
June 1, 2010;
41(6):
1079 - 1083.
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Chen, P. A. Jarzyna, G. A. F. van Tilborg, V. A. Nguyen, D. P. Cormode, A. Klink, A. W. Griffioen, G. J. Randolph, E. A. Fisher, W. J. M. Mulder, et al.
RGD peptide functionalized and reconstituted high-density lipoprotein nanoparticles as a versatile and multimodal tumor targeting molecular imaging probe
FASEB J,
June 1, 2010;
24(6):
1689 - 1699.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. C. Tardif, P. L. L'Allier, R. Ibrahim, J. C. Gregoire, A. Nozza, M. Cossette, S. Kouz, M. A. Lavoie, J. Paquin, T. M. Brotz, et al.
Treatment With 5-Lipoxygenase Inhibitor VIA-2291 (Atreleuton) in Patients With Recent Acute Coronary Syndrome
Circ Cardiovasc Imaging,
May 1, 2010;
3(3):
298 - 307.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Shimbo, P. Muntner, D. Mann, A. J. Viera, S. Homma, J. F. Polak, R. G. Barr, D. Herrington, and S. Shea
Endothelial Dysfunction and the Risk of Hypertension: The Multi-Ethnic Study of Atherosclerosis
Hypertension,
May 1, 2010;
55(5):
1210 - 1216.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. S. Rogers, K. Nasir, A. L. Figueroa, R. C. Cury, U. Hoffmann, D. A. Vermylen, T. J. Brady, and A. Tawakol
Feasibility of FDG Imaging of the Coronary Arteries: Comparison Between Acute Coronary Syndrome and Stable Angina
J. Am. Coll. Cardiol. Img.,
April 1, 2010;
3(4):
388 - 397.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Reininger, I. Bernlochner, S. M. Penz, C. Ravanat, P. Smethurst, R. W. Farndale, C. Gachet, R. Brandl, and W. Siess
A 2-Step Mechanism of Arterial Thrombus Formation Induced by Human Atherosclerotic Plaques
J. Am. Coll. Cardiol.,
March 16, 2010;
55(11):
1147 - 1158.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Klink, E. Lancelot, S. Ballet, E. Vucic, J.-E. Fabre, W. Gonzalez, C. Medina, C. Corot, W. J. M. Mulder, Z. Mallat, et al.
Magnetic Resonance Molecular Imaging of Thrombosis in an Arachidonic Acid Mouse Model Using an Activated Platelet Targeted Probe
Arterioscler Thromb Vasc Biol,
March 1, 2010;
30(3):
403 - 410.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Sommer, P. Regitnig, L. Koltringer, and G. A. Holzapfel
Biaxial mechanical properties of intact and layer-dissected human carotid arteries at physiological and supraphysiological loadings
Am J Physiol Heart Circ Physiol,
March 1, 2010;
298(3):
H898 - H912.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Gottlieb, J. M. Miller, A. Arbab-Zadeh, M. Dewey, M. E. Clouse, L. Sara, H. Niinuma, D. E. Bush, N. Paul, A. L. Vavere, et al.
The Absence of Coronary Calcification Does Not Exclude Obstructive Coronary Artery Disease or the Need for Revascularization in Patients Referred for Conventional Coronary Angiography
J. Am. Coll. Cardiol.,
February 16, 2010;
55(7):
627 - 634.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. S. Barua, F. Sy, S. Srikanth, G. Huang, U. Javed, C. Buhari, D. Margosan, and J. A. Ambrose
Effects of Cigarette Smoke Exposure on Clot Dynamics and Fibrin Structure: An Ex Vivo Investigation
Arterioscler Thromb Vasc Biol,
January 1, 2010;
30(1):
75 - 79.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Henderson and L. Lee
Chapter 1 The epidemiology and pathophysiology of coronary artery disease
Oxford Textbook of Interventional Cardiology,
January 1, 2010;
1(1):
med-9780199569083-chapter - med-9780199569083-chapter.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
M Sawabe, N Tanaka, K Nakahara, A Hamamatsu, K Chida, T Arai, K Harada, T Inamatsu, T Ozawa, M M Naka, et al.
High lipoprotein(a) level promotes both coronary atherosclerosis and myocardial infarction: a path analysis using a large number of autopsy cases
Heart,
December 15, 2009;
95(24):
1997 - 2002.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Sirol, P. R. Moreno, K.-R. Purushothaman, E. Vucic, V. Amirbekian, H.-J. Weinmann, P. Muntner, V. Fuster, and Z. A. Fayad
Increased Neovascularization in Advanced Lipid-Rich Atherosclerotic Lesions Detected by Gadofluorine-M-Enhanced MRI: Implications for Plaque Vulnerability
Circ Cardiovasc Imaging,
September 1, 2009;
2(5):
391 - 396.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Shimbo, W. Chaplin, S. Kuruvilla, L. T. Wasson, D. Abraham, and M. M. Burg
Hostility and Platelet Reactivity in Individuals Without a History of Cardiovascular Disease Events
Psychosom Med,
September 1, 2009;
71(7):
741 - 747.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Niccoli, F. Burzotta, L. Galiuto, and F. Crea
Myocardial No-Reflow in Humans
J. Am. Coll. Cardiol.,
July 21, 2009;
54(4):
281 - 292.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. R. Moreno, J. Sanz, and V. Fuster
Promoting Mechanisms of Vascular Health: Circulating Progenitor Cells, Angiogenesis, and Reverse Cholesterol Transport
J. Am. Coll. Cardiol.,
June 23, 2009;
53(25):
2315 - 2323.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Hyafil, J.-C. Cornily, J. H.F. Rudd, J. Machac, L. J. Feldman, and Z. A. Fayad
Quantification of Inflammation Within Rabbit Atherosclerotic Plaques Using the Macrophage-Specific CT Contrast Agent N1177: A Comparison with 18F-FDG PET/CT and Histology
J. Nucl. Med.,
June 1, 2009;
50(6):
959 - 965.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Suzuki, A. C. Yeung, and F. Ikeno
The Pre-Clinical Animal Model in the Translational Research of Interventional Cardiology
J. Am. Coll. Cardiol. Intv.,
May 1, 2009;
2(5):
373 - 383.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Ronald, Y. Chen, A. J.-L. Belisle, A. M. Hamilton, K. A. Rogers, R. A. Hegele, B. Misselwitz, and B. K. Rutt
Comparison of Gadofluorine-M and Gd-DTPA for Noninvasive Staging of Atherosclerotic Plaque Stability Using MRI
Circ Cardiovasc Imaging,
May 1, 2009;
2(3):
226 - 234.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Corti, A. J. Flammer, N. K. Hollenberg, and T. F. Luscher
Cocoa and Cardiovascular Health
Circulation,
March 17, 2009;
119(10):
1433 - 1441.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Undas, K. Szuldrzynski, K. E. Brummel-Ziedins, W. Tracz, K. Zmudka, and K. G. Mann
Systemic blood coagulation activation in acute coronary syndromes
Blood,
February 26, 2009;
113(9):
2070 - 2078.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. S Vasan
Commentary: C-reactive protein and risk prediction--moving beyond associations to assessing predictive utility and clinical usefulness
Int. J. Epidemiol.,
February 1, 2009;
38(1):
231 - 234.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Authors/Task Force Members, F. Van de Werf, J. Bax, A. Betriu, C. Blomstrom-Lundqvist, F. Crea, V. Falk, G. Filippatos, K. Fox, K. Huber, et al.
Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology:
Eur. Heart J.,
December 1, 2008;
29(23):
2909 - 2945.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Okazaki, M. Igarashi, M. Nishi, M. Sekiya, M. Tajima, S. Takase, M. Takanashi, K. Ohta, Y. Tamura, S. Okazaki, et al.
Identification of Neutral Cholesterol Ester Hydrolase, a Key Enzyme Removing Cholesterol from Macrophages
J. Biol. Chem.,
November 28, 2008;
283(48):
33357 - 33364.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Bedel, A. Negre-Salvayre, S. Heeneman, M.-H. Grazide, J.-C. Thiers, R. Salvayre, and F. Maupas-Schwalm
E-Cadherin/{beta}-Catenin/T-Cell Factor Pathway Is Involved in Smooth Muscle Cell Proliferation Elicited by Oxidized Low-Density Lipoprotein
Circ. Res.,
September 26, 2008;
103(7):
694 - 701.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Lipinski, K. C. Briley-Saebo, V. Mani, and Z. A. Fayad
"Positive Contrast" Inversion-Recovery With Oxide Nanoparticles-Resonant Water Suppression Magnetic Resonance Imaging: A Change for the Better?
J. Am. Coll. Cardiol.,
August 5, 2008;
52(6):
492 - 494.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J M U-King-Im, T Y Tang, A Patterson, M J Graves, S Howarth, Z-Y Li, R Trivedi, D Bowden, P J Kirkpatrick, M E Gaunt, et al.
Characterisation of carotid atheroma in symptomatic and asymptomatic patients using high resolution MRI
J. Neurol. Neurosurg. Psychiatry,
August 1, 2008;
79(8):
905 - 912.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Ohayon, G. Finet, A. M. Gharib, D. A. Herzka, P. Tracqui, J. Heroux, G. Rioufol, M. S. Kotys, A. Elagha, and R. I. Pettigrew
Necrotic core thickness and positive arterial remodeling index: emergent biomechanical factors for evaluating the risk of plaque rupture
Am J Physiol Heart Circ Physiol,
August 1, 2008;
295(2):
H717 - H727.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Calcagno, J.-C. Cornily, F. Hyafil, J. H.F. Rudd, K. C. Briley-Saebo, V. Mani, G. Goldschlager, J. Machac, V. Fuster, and Z. A. Fayad
Detection of Neovessels in Atherosclerotic Plaques of Rabbits Using Dynamic Contrast Enhanced MRI and 18F-FDG PET
Arterioscler Thromb Vasc Biol,
July 1, 2008;
28(7):
1311 - 1317.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. C. Briley-Saebo, P. X. Shaw, W. J.M. Mulder, S.-H. Choi, E. Vucic, J. G. S. Aguinaldo, J. L. Witztum, V. Fuster, S. Tsimikas, and Z. A. Fayad
Targeted Molecular Probes for Imaging Atherosclerotic Lesions With Magnetic Resonance Using Antibodies That Recognize Oxidation-Specific Epitopes
Circulation,
June 24, 2008;
117(25):
3206 - 3215.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Jimenez-Valero, R. Moreno, A. Sanchez-Recalde, G. Galeote, L. Calvo, A. Viana, E. Lopez de Sa, and J. Lopez-Sendon
Review: Avoiding restenosis: is there a role for glucocorticoids in the drug-eluting stent era?
Therapeutic Advances in Cardiovascular Disease,
June 1, 2008;
2(3):
137 - 146.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. R. BAKHRU and D. L. BHATT
INTERPRETING THE CHARISMA STUDY: What is the role of dual antiplatelet therapy with clopidogrel and aspirin?
Cleveland Clinic Journal of Medicine,
April 1, 2008;
75(4):
289 - 295.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Grundy
Metabolic Syndrome Pandemic
Arterioscler Thromb Vasc Biol,
April 1, 2008;
28(4):
629 - 636.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. S. Small, N. A. Farid, C. D. Payne, G. J. Weerakkody, Y. G. Li, J. T. Brandt, D. E. Salazar, and K. J. Winters
Effects of the Proton Pump Inhibitor Lansoprazole on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel
J. Clin. Pharmacol.,
April 1, 2008;
48(4):
475 - 484.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. W. Bedard, V. Clerin, N. Sushkova, B. Tchernychev, T. Antrilli, C. Resmini, J. C. Keith Jr., J. K. Hennan, N. Kaila, S. DeBernardo, et al.
Characterization of the Novel P-Selectin Inhibitor PSI-697 [2-(4-Chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo[h] Quinoline-4-carboxylic acid] in Vitro and in Rodent Models of Vascular Inflammation and Thrombosis
J. Pharmacol. Exp. Ther.,
February 1, 2008;
324(2):
497 - 506.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. M. Heikkila, S. Latti, M. J. Leskinen, J. K. Hakala, P. T. Kovanen, and K. A. Lindstedt
Activated Mast Cells Induce Endothelial Cell Apoptosis by a Combined Action of Chymase and Tumor Necrosis Factor-{alpha}
Arterioscler Thromb Vasc Biol,
February 1, 2008;
28(2):
309 - 314.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Shinohara, T. Yamashita, H. Tawa, M. Takeda, N. Sasaki, T. Takaya, R. Toh, A. Takeuchi, T. Ohigashi, K. Shinohara, et al.
Atherosclerotic plaque imaging using phase-contrast X-ray computed tomography
Am J Physiol Heart Circ Physiol,
February 1, 2008;
294(2):
H1094 - H1100.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. G. Spagnoli, E. Bonanno, G. Sangiorgi, and A. Mauriello
Role of Inflammation in Atherosclerosis
J. Nucl. Med.,
November 1, 2007;
48(11):
1800 - 1815.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. F. Bodary
Links Between Adipose Tissue and Thrombosis in the Mouse
Arterioscler Thromb Vasc Biol,
November 1, 2007;
27(11):
2284 - 2291.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. J. Westrick, M. E. Winn, and D. T. Eitzman
Murine Models of Vascular Thrombosis
Arterioscler Thromb Vasc Biol,
October 1, 2007;
27(10):
2079 - 2093.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. H. Goldbarg, S. Elmariah, M. A. Miller, and V. Fuster
Insights Into Degenerative Aortic Valve Disease
J. Am. Coll. Cardiol.,
September 25, 2007;
50(13):
1205 - 1213.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. G. Dickhout, S. M. Colgan, S. Lhotak, and R. C. Austin
Increased Endoplasmic Reticulum Stress in Atherosclerotic Plaques Associated With Acute Coronary Syndrome: A Balancing Act Between Plaque Stability and Rupture
Circulation,
September 11, 2007;
116(11):
1214 - 1216.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Nasir, L. J. Shaw, S. T. Liu, S. R. Weinstein, T. R. Mosler, P. R. Flores, F. R. Flores, P. Raggi, D. S. Berman, R. S. Blumenthal, et al.
Ethnic Differences in the Prognostic Value of Coronary Artery Calcification for All-Cause Mortality
J. Am. Coll. Cardiol.,
September 4, 2007;
50(10):
953 - 960.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Ohayon, O. Dubreuil, P. Tracqui, S. Le Floc'h, G. Rioufol, L. Chalabreysse, F. Thivolet, R. I. Pettigrew, and G. Finet
Influence of residual stress/strain on the biomechanical stability of vulnerable coronary plaques: potential impact for evaluating the risk of plaque rupture
Am J Physiol Heart Circ Physiol,
September 1, 2007;
293(3):
H1987 - H1996.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. J. Cao, A. M. Arnold, T. A. Manolio, J. F. Polak, B. M. Psaty, C. H. Hirsch, L. H. Kuller, and M. Cushman
Association of Carotid Artery Intima-Media Thickness, Plaques, and C-Reactive Protein With Future Cardiovascular Disease and All-Cause Mortality: The Cardiovascular Health Study
Circulation,
July 3, 2007;
116(1):
32 - 38.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Qiao, I. Ronen, J. Viereck, F. L. Ruberg, and J. A. Hamilton
Identification of Atherosclerotic Lipid Deposits by Diffusion-Weighted Imaging
Arterioscler Thromb Vasc Biol,
June 1, 2007;
27(6):
1440 - 1446.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. De Caterina, S. Husted, L. Wallentin, G. Agnelli, F. Bachmann, C. Baigent, J. Jespersen, S. D. Kristensen, G. Montalescot, A. Siegbahn, et al.
Anticoagulants in heart disease: current status and perspectives
Eur. Heart J.,
April 10, 2007;
(2007)
ehl492v1.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. K. Liao
Secondary Prevention of Stroke and Transient Ischemic Attack: Is More Platelet Inhibition the Answer?
Circulation,
March 27, 2007;
115(12):
1615 - 1621.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. H. Shishehbor, M. S. Lauer, I. M. Singh, D. P. Chew, J. Karha, S. J. Brener, D. J. Moliterno, S. G. Ellis, E. J. Topol, and D. L. Bhatt
In Unstable Angina or Non-ST-Segment Acute Coronary Syndrome, Should Patients With Multivessel Coronary Artery Disease Undergo Multivessel or Culprit-Only Stenting?
J. Am. Coll. Cardiol.,
February 27, 2007;
49(8):
849 - 854.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. P. Levy, J. E. Levy, S. Kalet-Litman, R. Miller-Lotan, N. S. Levy, R. Asaf, J. Guetta, C. Yang, K. R. Purushothaman, V. Fuster, et al.
Haptoglobin Genotype Is a Determinant of Iron, Lipid Peroxidation, and Macrophage Accumulation in the Atherosclerotic Plaque
Arterioscler Thromb Vasc Biol,
January 1, 2007;
27(1):
134 - 140.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Germain, M. C. Romanik, I. Guerra, S. Solari, M. S. Reyes, R. J. Johnson, K. Price, S. A. Karumanchi, and G. Valdes
Endothelial Dysfunction: A Link Among Preeclampsia, Recurrent Pregnancy Loss, and Future Cardiovascular Events?
Hypertension,
January 1, 2007;
49(1):
90 - 95.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Prabhakaran, T. Rundek, R. Ramas, M. S.V. Elkind, M. C. Paik, B. Boden-Albala, and R. L. Sacco
Carotid Plaque Surface Irregularity Predicts Ischemic Stroke: The Northern Manhattan Study
Stroke,
November 1, 2006;
37(11):
2696 - 2701.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. Houard, A. Leclercq, V. Fontaine, M. Coutard, J.-L. Martin-Ventura, B. Ho-Tin-Noe, Z. Touat, O. Meilhac, and J.-B. Michel
Retention and Activation of Blood-Borne Proteases in the Arterial Wall: Implications for Atherothrombosis
J. Am. Coll. Cardiol.,
October 27, 2006;
48(9_Suppl_A):
A3 - A9.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. De Caterina and M. Zimarino
Coronary artery remodelling in atherosclerosis: unfortunately unpredictable
Eur. Heart J.,
August 1, 2006;
27(15):
1761 - 1763.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Nishihira, T. Imamura, A. Yamashita, K. Hatakeyama, Y. Shibata, Y. Nagatomo, H. Date, T. Kita, T. Eto, and Y. Asada
Increased expression of interleukin-10 in unstable plaque obtained by directional coronary atherectomy
Eur. Heart J.,
July 2, 2006;
27(14):
1685 - 1689.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Stoll and M. Bendszus
Inflammation and Atherosclerosis: Novel Insights Into Plaque Formation and Destabilization
Stroke,
July 1, 2006;
37(7):
1923 - 1932.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. R. Moreno, K-R. Purushothaman, M. Sirol, A. P. Levy, and V. Fuster
Neovascularization in Human Atherosclerosis
Circulation,
May 9, 2006;
113(18):
2245 - 2252.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. R. Lucas, R. Korol, and C. J. Pepine
Inflammation in Atherosclerosis: Some Thoughts About Acute Coronary Syndromes
Circulation,
May 2, 2006;
113(17):
e728 - e732.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. G. Futterman and L. Lemberg
Coronary Endothelium: A Key to Life Expectancy
Am. J. Crit. Care.,
May 1, 2006;
15(3):
315 - 320.
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Ben-Yehuda
Upstream/Downstream: Glycoprotein IIb/IIIa in Non-ST-Segment Elevation Myocardial Infarction
J. Am. Coll. Cardiol.,
February 7, 2006;
47(3):
538 - 540.
[Full Text]
[PDF]
|
|
|
|
Top
Abstract
Nomenclature and evolving...